AZA和TSA对乳腺癌性激素受体基因表达调控的研究
摘要
乳腺癌是一种全身性疾病,极易早期发生血道转移,严重威胁着妇女的健康。乳腺癌的治疗原则相应地发生了巨大变革,由以往单纯局部治疗转入局部与全身相结合的综合治疗时代。内分泌治疗作为乳腺癌全身治疗的主要方法之一,因其疗效确切、副作用少和给药方便而倍受青睐。据统计,约45%乳腺癌患者因雌激素(ERα)受体阴性而失去了内分泌治疗这一有效的治疗模式,所以性激素受体是决定内分泌治疗疗效的关键因素。DNA的甲基化以及组蛋白的去乙酰化是表观遗传调控中一种重要的共价修饰,可能调控着激素受体基因的表达。目前关于乳腺癌中性激素受体基因表达调控的分子机制尚不十分清楚,为了进一步了解乳腺癌中性激素受体表达的转录调控和翻译后调节,我们进行了如下的研究。
研究目的
联合应用DNA甲基转移酶抑制剂(DNA methyltransferase inhibitor, DNMTi) 5-氮基-2-脱氧胞苷(5-aza-2’deoxycytidine,AZA)和组蛋白去乙酰化酶抑制剂(Histone deacetylase inhibitor,HDACi)曲古菌素A(trichostatin A,TSA)作用于乳腺癌细胞株SKBR-3,研究能否通过这两种药物诱导性激素受体原本阴性乳腺癌细胞株SKBR-3重新表达功能性的雌雄激素受体(ERα和AR),并探讨经过药物诱导重新表达激素受体的SKBR-3细胞增殖能力的变化以及对于内分泌治疗的敏感性的改变。另外,研究单药TSA能否引起乳腺癌细胞株SKBR-3和MCF-7中激素受体的改变,并探讨经过药物处理后其增殖能力的变化。
材料与方法
1.联合应用AZA和TSA或单药TSA作用于乳腺癌细胞系SKBR-3后,应用反转录聚合酶链式反应(Reverse transcription-Polymerase chain reaction ,RT-PCR)方法检测处理后SKBR-3细胞株ERα、PR、AR、pS2以及PSA的mRNA表达水平。
2. AZA与TSA联合处理乳腺癌细胞SKBR-3细胞爬片,单药TSA分别处理乳腺癌细胞SKBR-3或MCF-7细胞爬片。根据药物处理共分六组:①(Vehicle) SKBR-3组;②(AZA+TSA) SKBR-3组;③(Vehicle) MCF-7组;④(TSA) MCF-7组;⑤(Vehicle) SKBR-3组;⑥(TSA) SKBR-3组。通过细胞免疫化学(immunocytochemistry ,ICC)SP法来检测药物处理前后乳腺癌细胞中ERα、PR、AR、pS2及PSA的蛋白表达水平的改变。
3.通过水溶性四唑盐(water-soluble tetrazolium salt,WST)方法来检测乳腺癌细胞的增殖能力变化。
(1)AZA+TSA联合诱导SKBR-3细胞株后,以WST法测定不同浓度梯度(①vehicle②lnmol/L③10nmo1/L④l00nmol/L⑤1μmo1/L⑥l0μmo1/L)MA作用下肿瘤细胞的增殖能力,并确定疗效最佳的MA浓度。
(2)取疗效最佳的MA浓度,根据药物处理将AZA+TSA诱导前后乳腺癌细胞SKBR-3共分六组:①vehilce对照组;②AZA+TSA组;③AZA+TSA+E2组;④AZA+TSA+E2+TAM组;⑤AZA+TSA+E2+MA组;⑥AZA+TSA+E2+TAM+MA组,以WST法来测定各组肿瘤细胞增殖能力的变化。
(3)根据药物处理将单药TSA处理的乳腺癌细胞SKBR-3和MCF-7共分四个组:①(Vehicle) SKBR-3组;②(TSA)SKBR-3组;③(Vehicle)MCF-7组;④(TSA) MCF-7组。以WST法测定各组肿瘤细胞在12、24、48、72、96小时的增殖能力。
研究结果
1. AZA+TSA或TSA都能诱导激素受体阴性的乳腺癌细胞株SKBR-3重新表达ERα、AR、PR、pS2以及PSA的mRNA。单药组的mRNA水平低于双药组(p<0.05),二组的mRNA水平显著低于MCF-7对照组(p<0.01)。
2.药物处理后乳腺癌细胞株ERα、PR、AR、pS2以及PSA表达的蛋白水平的改变。
(1)经AZA+TSA诱导后SKBR-3细胞爬片中部分细胞重新表达ERα、AR、PR、pS2和PSA的蛋白,但表达程度远不及MCF-7细胞(p<0.01),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前减少,但未发现细胞爬片中细胞溶解现象。
(2)单药TSA处理后MCF-7细胞爬片中ERα、AR、PR、pS2和PSA的蛋白表达量较处理前明显减少(p<0.05),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前明显减少,部分细胞出现溶解现象。
(3)单药TSA处理后SKBR-3细胞爬片中不同程度的恢复ERα、AR、PR、PS2和PSA的蛋白表达,但表达程度也远不及TSA处理后MCF-7细胞爬片中的残留量(p<0.05),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前显著减少,绝大部分细胞出现溶解现象。
3.药物处理前后乳腺癌细胞的增殖能力。
(1)在不同浓度MA作用下,诱导后SKBR-3细胞株表现出不同的增殖能力,呈浓度效应关系,MA浓度越大肿瘤细胞增殖能力越弱,在10μmol/L时肿瘤细胞增殖能力最弱。
(2)药物AZA 2.5μmol/L+TSA 100ng/ml诱导后细胞株SKBR-3增殖能力下降(p<0.05);加入1nmol/L 17β-estrodial后,AZA+TSA+E2组细胞增殖能力略有上升,但无显著性差异(p>0.05);进一步加入TAM或MA ,与AZA+TSA+E2组相比,AZA+TSA+E2+TAM组和AZA+TSA+E2+MA组细胞增殖能力呈相似程度的下降(p<0.05);最后联合应用TAM和MA,与单药组相比, AZA+TSA+E2+TAM+MA组细胞增殖能力进一步下降(p<0.05)。
(3)经TSA处理后的SKBR-3细胞株的增殖能力于24h后开始逐渐较处理前降低,且呈时间效应关系,时间越长两组间增殖能力差异越显著;经TSA处理后的MCF-7细胞株的增殖能力于48h以后才开始逐渐较处理前减低,时间越长两组间增殖能力差异越显著;96h时TSA处理前后MCF-7细胞增殖能力降低的幅度也明显低于SKBR-3细胞株降低的幅度(OD值0.6387 vs 1.1437)(p<0.05)。
结论
1. AZA+TSA联合应用能诱导性激素受体全阴性的乳腺癌细胞SKBR-3重新表达功能性的ERα和AR;诱导后重新表达ERα和AR的SKBR-3表现出增殖能力下降,两药联合诱导对于肿瘤细胞有一定抑制作用,并恢复肿瘤细胞对雌激素的生长依赖和内分泌治疗的敏感性。
2.诱导后重新表达ERα和AR的SKBR-3恢复对孕激素治疗的敏感性,且呈浓度效应关系,即MA浓度越大肿瘤细胞增殖能力越弱。小剂量MA可以取得与TAM相同的疗效,二者联合应用疗效优于单药,说明两者联合应用具有协同作用,为以后乳腺癌患者接受他莫西芬治疗后妇科并发症的防治提供了实验依据。
3. TSA即可以通过诱导激素受体的表达提高受体阴性的乳腺癌患者对内分泌治疗的敏感性,也可以通过降解激素受体的途径治疗对内分泌治疗耐药的激素受体阳性患者。更重要的是提示,TSA可能既通过增强组蛋白的乙酰化水平,松解染色质的构象,重新激活抑癌基因的表达,又通过增强非组蛋白的乙酰化水平,抑制HSP90的分子伴侣功能,降解癌基因蛋白,介导肿瘤细胞的分化及凋亡,全方位、多环节地发挥抗肿瘤作用。这为HDAC抑制剂作为乳腺癌新型抗肿瘤药物提供了理论依据。
Backgroud
Breast cancer was known as a systemic disease because it often caused earlier hematogeneous metastasis,which heavily threatened women’s health. Accordingly,great change happened in the therapy strategy of breast cancer ,from the past local treatments alone to local and systemic treatment in combination. Endocrine therapy as one of systemic treatments was well welcomed because of its factual effects ,less adverse-effects and convenience. There were about 45% breast cancer patients would have lost the chance of endocrine therapy because estrogen receptor alpha ( ERa ) was negative.So we could drow that human sex hormone reccpters (SHR) were the main prognostic indicators of endocrine therapy. DNA methylation and histone acetylation are important covalent chromatin modification in epigenetic modification, which might regulate the expression of SHR gene. However,very little is known about the molecular mechanisms of the regulation of SHR gene expression itself.To better understand transcriptional and translational regulation of SHR gene expression,we carded out this study and the major results are summarized below.
Objective
To investigate whether DNMT inhibitor 5-AZA-CdR (AZA) and HDAC inhibitor tri- chostatin A(TSA) in combination can synergistically induce ERa and AR reexpression in initially Era- and AR- negative breast cancer cells SKBR-3 and restore its response to estrogen and endocrine therapy.Moreover,to investigate whether TSA can induce the chan- ge of ERa and AR expression level in SKBR-3 or MCF-7 cells and change their prolife- ration after chemical treatment.
Methods
1. The mRNA expression of ERa、PR、AR、pS2 and PSA in SKBR-3 cells treated with TSA and AZA in combination or TSA alone was detected by RT-PCR.
2. Human breast cancer cells SKBR-3 were treated with TSA and AZA in combina- tion,breast cancer cells SKBR-3 or MCF-7 were treated with TSA alone,and then there are six treatment groups established:①Group (Vehicle) SKBR-3,②Group (AZA+TSA) SKBR-3,③Group (Vehicle) MCF-7,④Group (TSA) MCF-7,⑤Group (Vehicle) SKBR-3,⑥Group (TSA) SKBR-3. The protein expression of ERa、PR、AR、pS2 and PSA in the treated SKBR-3 and MCF-7 cells was detected by immunocytochemistry(ICC) method.
3. The water-soluble tetrazolium salt (WST) method was used to analyze the cells proliferation.
(1) SKBR-3 cells proliferation treated with TSA and AZA in combination was ana- lyzed in the different concentration of megestrol acetate (MA):①vehicle,②lnmol/L,③10nmo1/L④l00nmol/L⑤1μmo1/L⑥l0μmo1/L.
(2) In the study of the combination treatment by AZA and TSA, there were six treat- ment groups in breast cancer cells SKBR-3 after the optimal concentration of megestrol acetate (MA) was established:①vehicle,②AZA+TSA,③AZA+TSA+E2,④AZA+TSA +E2+TAM,⑤AZA+TSA+E2+MA,⑥AZA+TSA+E2+TAM+MA.
(3)After the treatment by TSA alone ,there were four treatment groups established in breast cancer cells SKBR-3 and MCF-7:①(Vehicle)SKBR-3,②(TSA)SKBR-3,③(Vehicle)MCF-7,④(TSA)MCF-7.The proliferation rate of every group was analyzed at different time :12h, 24h, 48h , 72h, 96h.
Results
1. After treatment by AZA and TSA in combination or TSA alone, ERa、AR、PR、pS2 and PSA mRNA reexpressed in the initially ERa- and AR-negative breast cancer cells SKBR-3, whereas the mRNA expression level in the one chemical treatment was less than that in the combination treatment(P<0.05),and both of them was much less than that in MCF-7 cells(P<0.01).
2. In the protein expression analysis:
(1) After the combination treatment, ERa、PR、AR、pS2 and PSA protein re-expre- ssed in the initially ER- and AR-negotive SKBR-3 cells .The protein expression level indu- ced by AZA and TSA was much less than that in MCF-7 cells(P<0.01). In per field of high multiple vision(×400)in the glass plate where human breast cancer line SKBR-3 was se- eded,the number of cells present of AZA and TSA was less than that absent of the two che- micals.No cell death was found.
(2) After treatment by the one chemical, ERa、PR、AR、pS2 and PSA protein re-ex- pressed in the initially ERa- and AR- negative breast cancer cells SKBR-3 whereas they were suppressed in the initially ERa-and AR- positive breast cancer cells MCF-7.However, the protein expression level in SKBR-3 cells treated with TSA was less than the remainder in MCF-7 cells treated with TSA(P<0.05).More cells death was found in the glass plate where human breast cancer line SKBR-3 was seeded than that of breast cancer cells MCF -7.
3. In the proliferation rate analysis:
(1) Breast cancer cells SKBR-3 induced by AZA and TSA was treated for 96 hours by Megestrol acetate (MA) at different concentrations (1nmol/L–10μmol/L).The dose-resp- onse study demonstrated lower proliferation rate at the higher concentration of megestrol acetate (MA),the optimal concentration of MA was 10μmol/L.
(2) The growth of SKBR-3 cells treated with AZA and TSA was suppressed signifi- cantly compared with the vehicle control(P<0.05);and then 1nmol/L 17β-estrodial added, the proliferation rate of the induced cells was upregulated again but not significantly(p> 0.05); TAM or MA added respectively again ,the growth of cells treated with AZA +TSA +E2+ MA as well as AZA +TSA +E2+TAM was suppressed compared with AZA +TSA +E2 group (P < 0.05); At last, the growth of the induced cells treated with TAM and MA in combination was further suppressed than that of cells treated with TAM or MA alone (P<0.05).
(3)The growth of both SKBR-3 and MCF-7 cells was significantly suppressed by TSA alone compared with the vehicle group (P<0.05). In addition, the suppression of SKBR-3 cells proliferation rate by TSA happened much earlier and was much more than that of MCF-7 cells (24h vs 48h, OD 1.1437 vs 0.6387).
Conclusion
1.After treatment with AZA and TSA,ERa- and AR-negative SKBR-3 cells can ex- press functional ERa and AR and become responsive to estrogen and endocrine therapy , suggesting that the two chemicals may play important roles in restoring sensitivity of the SHR-negotive breast cancer to endocrinetherapy.Moreover,AZA and TSA could suppress SKBR-3 cells proliferation , suggesting that they could inhibits the growth of breast can- cer by changing its biology.
2.Breast cancer cells SKBR-3 chemically induced ERa and AR re-expression res- tored dose-response to MA, which demonstrated lower proliferation rate in higher concen- tration of megestrol acetate (MA). In addition, the combination treatment with TAM and MA could synergistically inhibit the growth of induced breast cancer cells via functional ER and AR ,respectively, suggesting that small dose of MA(8mg/d)often used in hormone replacement therapy (HRT) maybe a potent plus for postmenopausal patients treated with long-term TAM to prevent the most unpleasant adverse effect of TAM,raised risk of endo- metrial cancer. However, this hypothesis is just from an experiment in vitro and must be further certified by clinical trials.
3.TSA can not only improve sensitivity of the initially ERa and AR negative breast cancer cells to endocrine therapy by chemical induction of ERa and AR re-expression but also inhibit ERa and AR positive breast cancer cells growth by down-regulation of ERa and AR expression. It was more important to infer that TSA could not only induce the ex- pression of tumor suppressor genes but also down-regulate the expression of oncogenic protein to inhibit breast cancer cells proliferation by induction of their diffrention and apo- ptosis.
研究目的
联合应用DNA甲基转移酶抑制剂(DNA methyltransferase inhibitor, DNMTi) 5-氮基-2-脱氧胞苷(5-aza-2’deoxycytidine,AZA)和组蛋白去乙酰化酶抑制剂(Histone deacetylase inhibitor,HDACi)曲古菌素A(trichostatin A,TSA)作用于乳腺癌细胞株SKBR-3,研究能否通过这两种药物诱导性激素受体原本阴性乳腺癌细胞株SKBR-3重新表达功能性的雌雄激素受体(ERα和AR),并探讨经过药物诱导重新表达激素受体的SKBR-3细胞增殖能力的变化以及对于内分泌治疗的敏感性的改变。另外,研究单药TSA能否引起乳腺癌细胞株SKBR-3和MCF-7中激素受体的改变,并探讨经过药物处理后其增殖能力的变化。
材料与方法
1.联合应用AZA和TSA或单药TSA作用于乳腺癌细胞系SKBR-3后,应用反转录聚合酶链式反应(Reverse transcription-Polymerase chain reaction ,RT-PCR)方法检测处理后SKBR-3细胞株ERα、PR、AR、pS2以及PSA的mRNA表达水平。
2. AZA与TSA联合处理乳腺癌细胞SKBR-3细胞爬片,单药TSA分别处理乳腺癌细胞SKBR-3或MCF-7细胞爬片。根据药物处理共分六组:①(Vehicle) SKBR-3组;②(AZA+TSA) SKBR-3组;③(Vehicle) MCF-7组;④(TSA) MCF-7组;⑤(Vehicle) SKBR-3组;⑥(TSA) SKBR-3组。通过细胞免疫化学(immunocytochemistry ,ICC)SP法来检测药物处理前后乳腺癌细胞中ERα、PR、AR、pS2及PSA的蛋白表达水平的改变。
3.通过水溶性四唑盐(water-soluble tetrazolium salt,WST)方法来检测乳腺癌细胞的增殖能力变化。
(1)AZA+TSA联合诱导SKBR-3细胞株后,以WST法测定不同浓度梯度(①vehicle②lnmol/L③10nmo1/L④l00nmol/L⑤1μmo1/L⑥l0μmo1/L)MA作用下肿瘤细胞的增殖能力,并确定疗效最佳的MA浓度。
(2)取疗效最佳的MA浓度,根据药物处理将AZA+TSA诱导前后乳腺癌细胞SKBR-3共分六组:①vehilce对照组;②AZA+TSA组;③AZA+TSA+E2组;④AZA+TSA+E2+TAM组;⑤AZA+TSA+E2+MA组;⑥AZA+TSA+E2+TAM+MA组,以WST法来测定各组肿瘤细胞增殖能力的变化。
(3)根据药物处理将单药TSA处理的乳腺癌细胞SKBR-3和MCF-7共分四个组:①(Vehicle) SKBR-3组;②(TSA)SKBR-3组;③(Vehicle)MCF-7组;④(TSA) MCF-7组。以WST法测定各组肿瘤细胞在12、24、48、72、96小时的增殖能力。
研究结果
1. AZA+TSA或TSA都能诱导激素受体阴性的乳腺癌细胞株SKBR-3重新表达ERα、AR、PR、pS2以及PSA的mRNA。单药组的mRNA水平低于双药组(p<0.05),二组的mRNA水平显著低于MCF-7对照组(p<0.01)。
2.药物处理后乳腺癌细胞株ERα、PR、AR、pS2以及PSA表达的蛋白水平的改变。
(1)经AZA+TSA诱导后SKBR-3细胞爬片中部分细胞重新表达ERα、AR、PR、pS2和PSA的蛋白,但表达程度远不及MCF-7细胞(p<0.01),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前减少,但未发现细胞爬片中细胞溶解现象。
(2)单药TSA处理后MCF-7细胞爬片中ERα、AR、PR、pS2和PSA的蛋白表达量较处理前明显减少(p<0.05),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前明显减少,部分细胞出现溶解现象。
(3)单药TSA处理后SKBR-3细胞爬片中不同程度的恢复ERα、AR、PR、PS2和PSA的蛋白表达,但表达程度也远不及TSA处理后MCF-7细胞爬片中的残留量(p<0.05),且爬片中单位高倍视野内(ICC,×400)细胞数目较处理前显著减少,绝大部分细胞出现溶解现象。
3.药物处理前后乳腺癌细胞的增殖能力。
(1)在不同浓度MA作用下,诱导后SKBR-3细胞株表现出不同的增殖能力,呈浓度效应关系,MA浓度越大肿瘤细胞增殖能力越弱,在10μmol/L时肿瘤细胞增殖能力最弱。
(2)药物AZA 2.5μmol/L+TSA 100ng/ml诱导后细胞株SKBR-3增殖能力下降(p<0.05);加入1nmol/L 17β-estrodial后,AZA+TSA+E2组细胞增殖能力略有上升,但无显著性差异(p>0.05);进一步加入TAM或MA ,与AZA+TSA+E2组相比,AZA+TSA+E2+TAM组和AZA+TSA+E2+MA组细胞增殖能力呈相似程度的下降(p<0.05);最后联合应用TAM和MA,与单药组相比, AZA+TSA+E2+TAM+MA组细胞增殖能力进一步下降(p<0.05)。
(3)经TSA处理后的SKBR-3细胞株的增殖能力于24h后开始逐渐较处理前降低,且呈时间效应关系,时间越长两组间增殖能力差异越显著;经TSA处理后的MCF-7细胞株的增殖能力于48h以后才开始逐渐较处理前减低,时间越长两组间增殖能力差异越显著;96h时TSA处理前后MCF-7细胞增殖能力降低的幅度也明显低于SKBR-3细胞株降低的幅度(OD值0.6387 vs 1.1437)(p<0.05)。
结论
1. AZA+TSA联合应用能诱导性激素受体全阴性的乳腺癌细胞SKBR-3重新表达功能性的ERα和AR;诱导后重新表达ERα和AR的SKBR-3表现出增殖能力下降,两药联合诱导对于肿瘤细胞有一定抑制作用,并恢复肿瘤细胞对雌激素的生长依赖和内分泌治疗的敏感性。
2.诱导后重新表达ERα和AR的SKBR-3恢复对孕激素治疗的敏感性,且呈浓度效应关系,即MA浓度越大肿瘤细胞增殖能力越弱。小剂量MA可以取得与TAM相同的疗效,二者联合应用疗效优于单药,说明两者联合应用具有协同作用,为以后乳腺癌患者接受他莫西芬治疗后妇科并发症的防治提供了实验依据。
3. TSA即可以通过诱导激素受体的表达提高受体阴性的乳腺癌患者对内分泌治疗的敏感性,也可以通过降解激素受体的途径治疗对内分泌治疗耐药的激素受体阳性患者。更重要的是提示,TSA可能既通过增强组蛋白的乙酰化水平,松解染色质的构象,重新激活抑癌基因的表达,又通过增强非组蛋白的乙酰化水平,抑制HSP90的分子伴侣功能,降解癌基因蛋白,介导肿瘤细胞的分化及凋亡,全方位、多环节地发挥抗肿瘤作用。这为HDAC抑制剂作为乳腺癌新型抗肿瘤药物提供了理论依据。
Backgroud
Breast cancer was known as a systemic disease because it often caused earlier hematogeneous metastasis,which heavily threatened women’s health. Accordingly,great change happened in the therapy strategy of breast cancer ,from the past local treatments alone to local and systemic treatment in combination. Endocrine therapy as one of systemic treatments was well welcomed because of its factual effects ,less adverse-effects and convenience. There were about 45% breast cancer patients would have lost the chance of endocrine therapy because estrogen receptor alpha ( ERa ) was negative.So we could drow that human sex hormone reccpters (SHR) were the main prognostic indicators of endocrine therapy. DNA methylation and histone acetylation are important covalent chromatin modification in epigenetic modification, which might regulate the expression of SHR gene. However,very little is known about the molecular mechanisms of the regulation of SHR gene expression itself.To better understand transcriptional and translational regulation of SHR gene expression,we carded out this study and the major results are summarized below.
Objective
To investigate whether DNMT inhibitor 5-AZA-CdR (AZA) and HDAC inhibitor tri- chostatin A(TSA) in combination can synergistically induce ERa and AR reexpression in initially Era- and AR- negative breast cancer cells SKBR-3 and restore its response to estrogen and endocrine therapy.Moreover,to investigate whether TSA can induce the chan- ge of ERa and AR expression level in SKBR-3 or MCF-7 cells and change their prolife- ration after chemical treatment.
Methods
1. The mRNA expression of ERa、PR、AR、pS2 and PSA in SKBR-3 cells treated with TSA and AZA in combination or TSA alone was detected by RT-PCR.
2. Human breast cancer cells SKBR-3 were treated with TSA and AZA in combina- tion,breast cancer cells SKBR-3 or MCF-7 were treated with TSA alone,and then there are six treatment groups established:①Group (Vehicle) SKBR-3,②Group (AZA+TSA) SKBR-3,③Group (Vehicle) MCF-7,④Group (TSA) MCF-7,⑤Group (Vehicle) SKBR-3,⑥Group (TSA) SKBR-3. The protein expression of ERa、PR、AR、pS2 and PSA in the treated SKBR-3 and MCF-7 cells was detected by immunocytochemistry(ICC) method.
3. The water-soluble tetrazolium salt (WST) method was used to analyze the cells proliferation.
(1) SKBR-3 cells proliferation treated with TSA and AZA in combination was ana- lyzed in the different concentration of megestrol acetate (MA):①vehicle,②lnmol/L,③10nmo1/L④l00nmol/L⑤1μmo1/L⑥l0μmo1/L.
(2) In the study of the combination treatment by AZA and TSA, there were six treat- ment groups in breast cancer cells SKBR-3 after the optimal concentration of megestrol acetate (MA) was established:①vehicle,②AZA+TSA,③AZA+TSA+E2,④AZA+TSA +E2+TAM,⑤AZA+TSA+E2+MA,⑥AZA+TSA+E2+TAM+MA.
(3)After the treatment by TSA alone ,there were four treatment groups established in breast cancer cells SKBR-3 and MCF-7:①(Vehicle)SKBR-3,②(TSA)SKBR-3,③(Vehicle)MCF-7,④(TSA)MCF-7.The proliferation rate of every group was analyzed at different time :12h, 24h, 48h , 72h, 96h.
Results
1. After treatment by AZA and TSA in combination or TSA alone, ERa、AR、PR、pS2 and PSA mRNA reexpressed in the initially ERa- and AR-negative breast cancer cells SKBR-3, whereas the mRNA expression level in the one chemical treatment was less than that in the combination treatment(P<0.05),and both of them was much less than that in MCF-7 cells(P<0.01).
2. In the protein expression analysis:
(1) After the combination treatment, ERa、PR、AR、pS2 and PSA protein re-expre- ssed in the initially ER- and AR-negotive SKBR-3 cells .The protein expression level indu- ced by AZA and TSA was much less than that in MCF-7 cells(P<0.01). In per field of high multiple vision(×400)in the glass plate where human breast cancer line SKBR-3 was se- eded,the number of cells present of AZA and TSA was less than that absent of the two che- micals.No cell death was found.
(2) After treatment by the one chemical, ERa、PR、AR、pS2 and PSA protein re-ex- pressed in the initially ERa- and AR- negative breast cancer cells SKBR-3 whereas they were suppressed in the initially ERa-and AR- positive breast cancer cells MCF-7.However, the protein expression level in SKBR-3 cells treated with TSA was less than the remainder in MCF-7 cells treated with TSA(P<0.05).More cells death was found in the glass plate where human breast cancer line SKBR-3 was seeded than that of breast cancer cells MCF -7.
3. In the proliferation rate analysis:
(1) Breast cancer cells SKBR-3 induced by AZA and TSA was treated for 96 hours by Megestrol acetate (MA) at different concentrations (1nmol/L–10μmol/L).The dose-resp- onse study demonstrated lower proliferation rate at the higher concentration of megestrol acetate (MA),the optimal concentration of MA was 10μmol/L.
(2) The growth of SKBR-3 cells treated with AZA and TSA was suppressed signifi- cantly compared with the vehicle control(P<0.05);and then 1nmol/L 17β-estrodial added, the proliferation rate of the induced cells was upregulated again but not significantly(p> 0.05); TAM or MA added respectively again ,the growth of cells treated with AZA +TSA +E2+ MA as well as AZA +TSA +E2+TAM was suppressed compared with AZA +TSA +E2 group (P < 0.05); At last, the growth of the induced cells treated with TAM and MA in combination was further suppressed than that of cells treated with TAM or MA alone (P<0.05).
(3)The growth of both SKBR-3 and MCF-7 cells was significantly suppressed by TSA alone compared with the vehicle group (P<0.05). In addition, the suppression of SKBR-3 cells proliferation rate by TSA happened much earlier and was much more than that of MCF-7 cells (24h vs 48h, OD 1.1437 vs 0.6387).
Conclusion
1.After treatment with AZA and TSA,ERa- and AR-negative SKBR-3 cells can ex- press functional ERa and AR and become responsive to estrogen and endocrine therapy , suggesting that the two chemicals may play important roles in restoring sensitivity of the SHR-negotive breast cancer to endocrinetherapy.Moreover,AZA and TSA could suppress SKBR-3 cells proliferation , suggesting that they could inhibits the growth of breast can- cer by changing its biology.
2.Breast cancer cells SKBR-3 chemically induced ERa and AR re-expression res- tored dose-response to MA, which demonstrated lower proliferation rate in higher concen- tration of megestrol acetate (MA). In addition, the combination treatment with TAM and MA could synergistically inhibit the growth of induced breast cancer cells via functional ER and AR ,respectively, suggesting that small dose of MA(8mg/d)often used in hormone replacement therapy (HRT) maybe a potent plus for postmenopausal patients treated with long-term TAM to prevent the most unpleasant adverse effect of TAM,raised risk of endo- metrial cancer. However, this hypothesis is just from an experiment in vitro and must be further certified by clinical trials.
3.TSA can not only improve sensitivity of the initially ERa and AR negative breast cancer cells to endocrine therapy by chemical induction of ERa and AR re-expression but also inhibit ERa and AR positive breast cancer cells growth by down-regulation of ERa and AR expression. It was more important to infer that TSA could not only induce the ex- pression of tumor suppressor genes but also down-regulate the expression of oncogenic protein to inhibit breast cancer cells proliferation by induction of their diffrention and apo- ptosis.
引文
[1]陈承祺,吉国力,陈舒婷,等.绝经前乳腺疾病患者性腺轴系激素水平量化分析及其临床意义[J].中华肿瘤防治杂志,2008,15(18):1404-1407.
[2] James D,Yager PHD,Nancy E,et al . Estrogen Carcinogenesis in Breast cancer [J]. Nengl T Med ,2006 ,354:270-282.
[3]马小平,徐冰,戴淑真,等.孕激素对乳腺癌细胞中雌激素代谢酶的影响[J].中国妇幼保健,2009,24(16):2263-2266.
[4]胡名柏,谢伟,熊斌,等.血浆类固醇性激素水平与女性乳腺癌危险性的关系[J].武汉大学学报(医学版),2004,25(6):694-697.
[5] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2): 200-214.
[6]林青,李华.血清雌二醇睾酮水平与女性乳腺癌的关系[J].山东医学高等专科学校学报,2006,28(4):259-261.
[7]孙秀,李海平,李云涛,等.血清睾酮水平与绝经后乳腺癌转移复发及预后的关系[J].山东医药2009,49(36):36-38.
[8] Micheli A, Meneghini E, Secreto G, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients [J]. J Clin Oncol, 2007, 25(19):2685-2690.
[9] Berrino F, Pasanisi P, Bellati C, et al. Serum testosterone levels and breast cancer recurrence [J].Int J Cancer,2005,113(3):499-502.
[10] Pasanisi P, Berrino F, De PetrisM, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences [J].Int J Cancer, 2006, 119(1):236-238.
[11] Xie B , Tsao SW,Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17 beta-oestradiol and testosterone [J].Carci- nogenesis,1999,20(8):1069-1078.
[12] Robinson-Rechavi M,Escriva Garcia H,Laudet V. The nuclear receptor superfamily. J Cell Sci,2003,116(4):585-586.
[13] Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer[ J].Cancer Res, 1999,59(21):5425-5428.
[14]罗仁峰.乳腺癌组织pS2与雌激素和孕激素受体的关系及预后意义[J].亚太传统医药,2008,4(7):11-12.
[15] Maynadier M, NirdéP, Ramirez JM, et al. Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells [J]. Adv Exp Med Biol,2008,617:485- 491.
[16] Cui XJ, Schiff R, Arpino G, et al.Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23:7721-7735.
[17] Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J]. Breast,2003,12:362-367.
[18] Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive,progesterone receptor negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance[J]. J Natl Cancer Inst , 2005,97:1254-1261.
[19]王圆,叶剑飞,方文星.ER+/ PR+、ER+/ PR-乳腺癌的临床病理特征及预后分析[J].现代肿瘤医学,2009,4(4):1-4.
[20] Dowsett M. On behalf of the ATAC trialists group: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status[J]. Breast Cancer Res Treat, 2003 (suppl 1),82:S7.
[21] Bardou VJ, Arpino G, Elledge RM, et al.Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer data bases[J].J Clin Oncol,2003,21:1973- 1979.
[22] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer,the so-called triple-negative phenotype: a population-based study from the California Cancer Registry [J]. Cancer, 2007,109(9):1721-1728.
[23] Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor- negative,invasive breast cancer: the California Cancer Registry,1999-2004 [J].Cancer, 2008,112(4):737-747.
[24] Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J].Breast Cancer Res Treat,2008,111(1):27-44.
[25] Keen JC,Yan L,Mack KM,et al.A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine[J].Breast Cancer Res Treat,2003,81(3):177-186.
[26]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[27] Riva C,Dainese E,Caprara G. Study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma[J] . Vimhows Arch,2005, 447(4):695-700.
[28] Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the HER-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway[J].Mol Cell Biol,2004,24(19):8681-8690.
[29] Madureira PA,Varshochi R,Constantinidou D,et al.The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells[J].J Biol Chem,2006,281(35):25167-25176.
[30]陈蕾,徐绮腻,郑瑾,等.乳腺癌临床特征与预后分析[J].中华肿瘤防治杂志,2007,14(15):1159-1162.
[31] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[32] Fan J,Yin WJ,Lu JS,et al.ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor[J].J Cancer Res Clin Oncol,2008,134(8) :883-890.
[33] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancercells[J].Cancer Res,1998,58(23): 5310-5314.
[34]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067 -1070.
[35] Raphae ML , Vanessa D, Audrey C, et al. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells[J]. Biochemical Pharmacology, 2004, 68(4): 1239.
[36] Yu X, Guo ZS,Marcu MG, et al. Modulation of p53, ErbB1,ErbB2, and Raf-1 expression in lung cancer cells of depsipeptide FR901228 [J].J Natl Cancer Inst,2002, 94(7): 504-513.
[37] Fuino L,Bali P,Wittmann S,et al. Histone deacetylase inhibitor LAQ824 down- regulates HER-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B [J]. Mol Cancer Ther, 2003,2(10):971-984.
[38] Reid G,Metivier R,Lin CY,et al. Multiplemechanisms induce transcriptional silencing of a subsetofgenes, including oestrogenreceptor a, in response to deacetylase inhibit- tion by valproic acidand trichostatin A [J]. Oncogene,2005,24(31):4894-4907.
[39]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J].中国临床药理学与治疗学,2006,11(9):1013-1016.
[40] Gomez BP,Riggins RB,Shajahan AN,et al.Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines[J]. FASEB J,2007,21(14):4013-4027.
[41] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[1]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067 -1070.
[2] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2): 200-214.
[3]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[4] Toth FS,Cheek J,Calhoun K,et a1.Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool[J].Arch Surg,2004,139(1):5O-54.
[5] Garreau JR,Muller P,Pommier R.Transgetic introduction of androgen receptor into estrogen-receptor-,progesterone-receptor-,and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation [J].Am J Surg, 2006, 191(5):576-580.
[6]刘铁成,李德春.乳腺癌中pS2、PSA与其他预后因素的相关性[J].江苏医药,2010,36(23):2757-2759.
[7] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[8] Ottoviano YL,Issa JP,Parl FF,et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells[J].Can- cer Res,1994,54(10):2552-2555.
[9] Lapidas RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation- specific polymerase chain reaction[J]. Cancer Res,1998,58 (12):2515- 2519.
[10] Zhao L,Wang L,Jin F,et al.Silencing of estrogen receptor alpha(ERalpha)gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer[J].Breast Cancer Res Treat,2009,117(2) :253-259.
[11] Yan L,Nass SJ,Smith D,et al.Specific inhibition of DNMT1 by antisense oligonucleo- tides induces re-expression of estrogen receptor-alpha(ER) in ER-negative human breast cancer cell lines[J].Cancer Biol Ther,2003,2(5) :552-556.
[12] Fu XH, Liu DP, Liang CC. Chromatin structure and transcription regulation of theβ-globin locus[J]. Exp Cell Res,2002,278(1):1.
[13] Berger SL. Histone modifications in transcriptional regulation[J]. Curr Opin Genet, 2002,12:142.
[14] Jenuwein T, Allis CD. Translating the histone code[J]. Science,2001,293(5532): 1074.
[15] Stiehl DP, Fath DM, Liang D, et al. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. Cancer Res. 2007,67:2256–2264.
[16] Hochedlinger K, Blelloch R, Brennan C,et al. Reprogramming of amelalloma genome by nuclear transplantation [J]. Genes Dev,2004,1(8): 1875-1885.
[17] Suzuki J,Chen YY,Scott GK,et al.Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression[J].Clin Cancer Res, 2009,15(9):3163-3171.
[18] Kawai H,Li H,Avraham S,et al.Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha[J].Int J Cancer,2003,107(3):353-358.
[19] Yang X,Ferguson AT,Nass SJ,et al.Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition[J].Cancer Res, 2000,60(24):6890-6894.
[20] Fuks F,Hurd PJ,Wolf D,et al.The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation[J].J Biol Chem,2003,278(6):4035-4040.
[21] Sharma D,Blum J,Yang X,et al.Release of methyl CpG binding proteinsand histone deacetylase 1 from the Estrogen receptor alpha (ER)promoter upon reactivation in ER-negative human breast cancer cells[J].Mol Endocrinol,2005,19(7):1740-1751.
[22] Keen JC,Yan L,Mack KM,et al.A novel histone deacetylase inhibitor,scriptaid,enhances expression of functional estrogen receptor alpha(ER) in ER negative human breast cancer cells in combination with 5-aza2’-deoxycytidine[J].Breast Cancer Res Treat,2003,81(3):177-186.
[23] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancer cells[J].Cancer Res,1998,58(23): 5310-5314.
[24] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[25] Ferguson AT,Lapidus RG,Davidson NE.Demethylation of the progesterone receptor CPG island is not required to progesterone receptor gene expression[J]. Oncogene, 1998,17(5):577-583.
[26] Lapidus RG,Ferguson AT,Ottallano YL,et al.Methylation of estrogen and progestero- ne receptor gene 5’CPG islands with lack of estrogen and progesterone receptor gene expression in breast tumors[J].Clin Cancer Res,1996,2(5):805-810.
[27]刘铁成,李德春,陶仪声,等.乳腺癌中pS2与PSA相关性的研究[J].中华全科医学,2009,7(10):1024-1025.
[28] Fan J,Yin WJ,Lu JS,et al.ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor[J].J Cancer Res Clin Oncol,2008,134(8):883-890.
[29] Ishiguro K,Sartorelli AC.Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/ a poptosis-dimethylsulfoxide,hexamethylene bisacetamide and trichostatin A[J].Eur J Biochem,2004,271(12): 2379-2390.
[30]范江,陆劲松,沈镇宙,等.5-aza-2’-deoxycytidine联合trichostatin A抑制乳腺癌细胞增殖能力的研究[J].中国癌症杂志,2006,16(5):329-332.
[31] Hortobagyi GN. Treatment of breast cancer[J].N Engl J Med, 1998, 339: 974–984.
[32]江明,邵志敏,张亚伟等.ER阳性和ER阴性人乳腺癌细胞株p53、mdm-2、及p21WAFI蛋白表达的研究[J].中华病理学杂志,1997,12(6):327-330.
[33] Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment[J].Gynecol Oncol,2004,94(2):256-266.
[34] Gayther SA,Batley SJ,Linger,et al. Mutations truncating the P300 acetylase in human cancers[J].Nat Genet,2000,24(3):300.
[35] Zheng L,Annab LA,Afshari CA,et al. BRCA1 mediates ligand-independent transcri- ptional repression of the estrogen receptor[J]. Proc Natl Acad Sci USA,2001,98(17): 9587.
[36] Margueron R,Duong V,Bonnet S,et al. Histone deacetylase activity and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens[J].J Mol Endocrinol,2004,32(2):1957.
[37] Christian M,Tullet JM,Parker MG. Characterisation of four autonomous repression domains in the corepressor RIP140[J]. J Biol Chem, 2004, 279(8):15645.
[38] Castet A,Boulahtouf A,Versini G,et al. Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibittion[J]. Nucl Acids Res,2004,32(5): 1957.
[39] Kurtev V,Margueron R,Kroboth K,et al. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases [J]. J Biol Chem , 2004,279(21):24834.
[40] Raphae Ml , Vanessa D, Audrey C, et al. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells[J]. Biochemical Pharmacology, 2004, 68(4): 1239.
[41] Cameron EE,Bachman KE,Myohamens.Synergy of demethylation and histone deace- tylase inhibition in the re-expression of genes silenced in cancer[J].Nat Genet,1999, 21(1):103-107.
[42] Yuan Y, Qin L, Liu D, et al. Genetic screening reveals an essential role of p27Kip1in restriction of breast cancer progression[J]. Cancer Res,2007,67(17):8032-8042.
[43]谢瑞莲,管晓翔,陈龙邦,等.丁酸钠对人乳腺癌细胞株MCF-7细胞增殖及p27Kip1蛋白表达影响的研究[J].中华肿瘤防治杂志,2008,15(14):1041-1044.
[44]邓放,王广义,任强.MS-275与表阿霉素合用对乳腺癌MCF-7细胞的影响[J].中国妇幼保健,2007,22(31):4466-4468.
[45] Holger HS, Tomke UB, David H,et al. MS-275, a potent orally vailable inhibitor of histone deacetylases-The development of an anticancer agent[J]. Int J Bio & Cell Bio, 2007,16:23
[46] Reid G,Metivier R,Lin CY,et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor a, in response to deacetylase inhi- bittion by valproic acidand trichostatin A [J]. Oncogene,2005,24(31):4894-4907.
[47] Fuino L,Bali P,Wittmann S,et al. Histone deacetylase inhibitor LAQ824 down - regulates HER-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B [J]. Mol Cancer Ther, 2003,2(10):971-984.
[48]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J ].中国临床药理学与治疗学,2006,11(9):1013- 1016.
[49] Byrd JC, Marcucci G, Parthun MR,et al. Aphase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acutemyeloid leukemia [J].Blood,2005,105(3):959-967.
[50]易欣,赵名,张旭辉,等.组蛋白去乙酰化酶抑制剂FK228通过阻断HSP90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5):349-353.
[51] Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J].J Cell Mol Med,2005,9(2):360-372.
[52] Reid T, Valone F, Lipera W,et al. PhaseⅡtrial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer [J]. Lung Cancer,2004, 45(3):381-386.
[53] Yu X, Guo ZS,Marcu MG, et al. Modulation of p53, ErbB1,ErbB2, and Raf-1 expre- ssion in lung cancer cells of depsipeptide FR901228 [J]. J Natl Cancer Inst,2002,94 (7): 504-513.
[54] Lee MO,Kim EO,Kwon HJ,et al. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shockprotein 90[J]. Mol Cell Endocrinol, 2002, 188(1-2): 47-54.
[55] Franco S,Perez A,Tan-Chiu E,et al. Response to fulvestrant in heavily pretreated postmenopausalwomen:a single center experience[J]. Breast Cancer Res Treat,2004, 88(2): 103-108.
[56] Moradei O, Maroun CR, Paquin I,et al. Histone deacetylase inhibitors: latest developments, trends and prospects[J]. Curr Med Chem Anticancer Agents,2005,5 (5):529-560.
[57] Schiff R,Massarweh S,Shou J,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen geldanamycin and tamoxifen-resistant breast cancer receptor coregulators modulate response [J]. Clin Cancer Res,2003,9(1Pt2):447-454.
[58] Colleoni M,Viole G, Zahrieh D,et al.Expression of ER, PgR,HER1,HER-2, and response: a study of preoperative chemotherapy[J].Ann Oncol, 2008,19(3):465-72.
[59] Dowsett M,Allred C,Knox J,et al.Relationship between quantitativeestrogen and pro- gesterone receptor expression and human epidermal growthfactor receptor2 (HER-2) status with recurrence in the Arimidex,Tamoxifen,Alone or in combination trial[J].J Clin Oncol,2008,26:1059-1065.
[60]唐鹏编译.美国ASCO年会拾贝:一种新型的组蛋白脱乙酰基酶抑制剂OSU-HDAC42对HER-2阳性乳腺癌有抗肿瘤作用[J/CD].中华乳腺病杂志(电子版),2009,3(5):568.
[61]王丹,陈宇鹏,梁静等.HDAC抑制剂TSA抑制乳腺癌MCF-7细胞增殖并促进乳腺癌细胞凋亡[J].中国生物化学与分子生物学报,2009,25(6):570-573.
[1] Peedicayil J.The role of epigenetics inmental disorders[J]. Indian J Med Res,2007,126 (2):105-111.
[2] Arts J,de Schepper S,Van Emelen K.Histone deacetylase inhibitors:from chromatin remodeling to experimentalcancer therapeutics[J].Curr Med Chem,2003,10(22): 2343-2350.
[3] Jair KW,Bachman KE,Suzuki H,et al.Denovo CpG island methylation in human cancer cells[J]. Cancer Res,2006,66(2):682-692.
[4]周小娟,王云梅,刘娟,等.5-氮杂-2′-脱氧胞苷逆转RASSF1A基因甲基化对人乳腺癌MCF-7细胞的影响[J].第四军医大学学报,2009,30(21):2327-2331.
[5] Robertson KD.DNA Methylation and Human Disease[J].Nat Rev Genet,2005,6 (8): 597-610.
[6] Okuda Y, Kawakami K, Ishiguro K,et al. The profile of hMLH1 methylation and microsatellite instability in colorectal and non-small cell lung cancer[J].Int Mol Med,2005,15(1):85-90.
[7] Erdamar S,Ucaryilmaz E, Dogusoy G. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer[J].World J Gastroenterol,2007,13(33):4437-4444.
[8] Jeon CH,Lee HI,Shin IH.Genetic alterations of APC,K-ras,p53,MSI, and MAGE in Korean colorectal cancer patients [J]. Int J Colorectal Dis, 2008, 23(1): 29-35.
[9] Schmutte C ,Yang AS,Beart RW,et al. Base excission repair of U:GMismatches at a mutational hotspot in the P53 gene is more efficient than base excision repaire of T:G mismatches in extracts of human colon tu-mors [J]. Cancer Res, 1995, 55 (17) : 3742- 3746.
[10] Mamatha G,Joseph B,Shanmugam MP,et al. CGA codonsmultiplex PCR in rapid diagnosis of retinoblastoma[J].Indian J Hum Genet,2006,12(1): 34-38.
[11] Luczak MW, Jagodzinski PP.The role of DNA methylation in cancer development[J]. Folia Histochem Cytobiol,2006,44(3):143-154.
[12] Polanowska J,Martin JS,Garcia-Muse T,et al. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage site[J].EMBO J, 2006,25(10):2178 -2188.
[13] Agrawal S,Unterberg M,Koschmieder S.DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia[J].Cancer Res,2007,67(3):1370-1377.
[14] Issa JP.DNA Methylation as a therapeutic target in cancer[J].Clin Cancer Res,2007,13 (6):1634-1637.
[15] Chen RZ,Pettersoon U,Beard C,et al. DNA hypomethylation leads to elevated mutation rates[J].Nature,1998,395(6697):89-93.
[16] Lengauer C,Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells[J]. Proc Natl Acad Sci USA,1997,9(4): 2545-2550.
[17] Brueckner B,Stresemann C,Kuner R,et al.The human let-7a-3 locus contains an epigentically regulated microRNA gene with oncogenic function[J].Cancer Res,2007, 67(14):19-23.
[18] Luo D, Zhang B,Lv L,et al. Methylation of CpG island of p16 associated with progression of primary gastric carcinomas[J].Lab Invest, 2006, 86(6): 591-598.
[19] Beier V,Mund C,Hoheisel JD. Monitoring methylation changes in cancer[J]. Adv Biochem Eng Biotechnol,2007,10(4):1-11.
[20] Esteller T. Detection and interpretation of altered methylation patterns in cancer cells[J].N Engl J Med,2008,358(11):48-59.
[21] Hochedlinger K, Blelloch R, Brennan C,et al. Reprogramming of amelalloma genome by nuclear transplantation [J]. Genes Dev,2004,1(8): 1875-1885.
[22] Gayther SA,Batley SJ,Linger,et al. Mutations truncating the P300 acetylase in human cancers [J].Nat Genet,2000,24(3):300.
[23] Zheng L,Annab LA,Afshari CA,et al. BRCA1 mediates ligand-independent transcrip-tional repression of the estrogen receptor [J]. Proc Natl Acad Sci USA,2001,98(17): 9587.
[24] Wang L,Devarajan E,He J,et al. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression[J].Cancer Res,2005,65(22):10289-10297.
[25]王磊,胡英,杨祖立,等.乳腺癌细胞中Syk( L)调节基因转录的生物学机制[J].癌症,2007,26(5):469-472.
[26] Margueron R,Duong V,Bonnet S,et al. Histone deacetylase activity and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens[J].J Mol Endocrinol,2004,32(2):1957.
[27] Christian M,Tullet JM,Parker MG. Characterisation of four autonomous repression domains in the corepressor RIP140[J]. J Biol Chem, 2004, 279(8):15645.
[28] Castet A,Boulahtouf A,Versini G,et al. Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibittion [J]. Nucl Acids Res,2004,32 (5): 1957.
[29] Kurtev V,Margueron R,Kroboth K,et al. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases [J]. J Biol Chem , 2004,279(21):24834.
[30]蔡飏,孙晋枫,黄朝晖,等.ABCC8、CHFR、BMP3B、LOX、PRSS21和RASSF1A基因启动子的甲基化状态可能与3种乳腺癌细胞株对5-FU的敏感性相关[J].肿瘤,2009,29(1):20-25.
[31]范江,陆劲松,沈镇宙,等.5-aza-2’-deoxycytidine联合trichostatin A抑制乳腺癌细胞增殖能力的研究[J].中国癌症杂志,2006,16(5):329-332.
[32] Chuang JC,Yoo CB,Kwan JM,et al.Comparison of biological effects of non-nucleo- side DNA methylation inhibitors versus 5-aza-2-deoxycytidine [J].Mol Cancer Ther, 2005,4(10):1515-1521.
[33] Segura Pacheco B,Trejo Becerril C,Perez Cardenas E,et al.Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy[J]. Clin Cancer Res,2003,9(5):1596-1603.
[34]任香,罗达亚,刘丽乔,等.肼苯哒嗪对人乳腺癌细胞株MDA-MB-231雌激素受体α去甲基化的影响[J].江西医学院学报,2009,49(3):26-29.
[35]陈伟,王留兴,樊青霞,等.三氧化二砷和肼苯哒嗪体外诱导雌激素受体表达强弱的比较[J].肿瘤基础与临床,2007,20(3):208-209.
[36]王丹,陈宇鹏,梁静等.HDAC抑制剂TSA抑制乳腺癌MCF-7细胞增殖并促进乳腺癌细胞凋亡[J].中国生物化学与分子生物学报,2009,25(6):570-573.
[37] Yuan Y, Qin L, Liu D, et al. Genetic screening reveals an essential role of p27Kip1in restriction of breast cancer progression[J]. Cancer Res,2007,67(17):8032-8042.
[38]谢瑞莲,管晓翔,陈龙邦,等.丁酸钠对人乳腺癌细胞株MCF-7细胞增殖及p27Kip1蛋白表达影响的研究[J].中华肿瘤防治杂志,2008,15(14):1041-1044.
[39]邓放,王广义,任强.MS-275与表阿霉素合用对乳腺癌MCF-7细胞的影响[J].中国妇幼保健,2007,22(31):4466-4468.
[40] Holger HS, Tomke UB, David H,et al. MS-275,a potent orally vailable inhibitor of histone deacetylases-The development of an anticancer agent[J]. Int J Bio & Cell Bio,2007,16:23
[41]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J ].中国临床药理学与治疗学,2006,11(9):1013- 16.
[42] Byrd JC, Marcucci G, Parthun MR,et al. Aphase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acutemyeloid leukemia [J].Blood,2005,105(3):959-967.
[43]易欣,赵名,张旭辉,等.组蛋白去乙酰化酶抑制剂FK228通过阻断HSP90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5):349-353.
[44] Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J]. J Cell Mol Med,2005,9(2):360-372.
[45] Fuks F,Hurd PJ,Wolf D,et al.The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation[J].J Biol Chem,2003,278(6):4035-4040.
[46] Cameron EE,Bachman KE,Myohamens.Synergy of demethylation and histone deace- tylase inhibition in the re-expression of genes silenced in cancer[J].Nat Genet,1999,21(1):103-107.
[47] Lapidas RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation- specific polymerase chain reaction[J]. Cancer Res,1998,58(12): 2515- 2519.
[48] Zhao L,Wang L,Jin F,et al.Silencing of estrogen receptor alpha(ERalpha)gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer[J].Breast Cancer Res Treat,2009,117(2):253-259.
[49] Yan L,Nass SJ,Smith D,et al.Specific inhibition of DNMT1 by antisense oligonucleo- tides induces re-expression of estrogen receptor-alpha(ER) in ER-negative human breast cancer cell lines[J].Cancer Biol Ther,2003,2(5):552-556.
[50] Suzuki J,Chen YY,Scott GK,et al.Protein acetylation and histone deacetylase expre- ssion associated with malignant breast cancer progression[J].Clin Cancer Res,2009, 15(9):3163-3171.
[51] Kawai H,Li H,Avraham S,et al.Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha [J].Int J Cancer,2003,107(3):353-358.
[52] Yang X,Ferguson AT,Nass SJ,et al.Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition[J]. Cancer Res, 2000,60(24):6890-6894.
[53] Sharma D,Blum J,Yang X,et al.Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER)promoter upon reactivation in ER-negative human breast cancer cells[J].Mol Endocrinol,2005,19(7):1740-1751.
[54] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[59] Woodfield GW,Horan AD,Chen Y,et al.TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling[J].Cancer Res,2007,67 (18):8439-8443.
[60] Woodfield GW,Hitchler MJ,Chen Y,et al.Interaction of TFAP2C with the estrogenreceptor-alpha promoter is controlled by chromatin structure[J].Clin Cancer Res, 2009,15(11):3672-3679.
[61] Angeloni SV,Martin MB,Garcia-Morales P,et al. Regulation of estrogen receptor- alpha expression by the tumor suppressor gene p53 in MCF-7cells [J]. J Endocrinol, 2004,180(3):497-504.
[62] Gomez BP,Riggins RB,Shajahan AN,et al.Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines[J]. FASEB J,2007,21(14):4013-4027.
[63] Adams BD,Furneaux H,White BA.The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha(ER-a)and represses ER-alpha messenger RNA and protein expression in breast cancer cell lines[J].Mol Endocrinol,2007,21,(5) :1132-1147.
[64] Kondo N,Toyama T,Sugiura H,et al. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer[J].Cancer Res,2008,68 (13): 5004-5008.
[65] Zhao JJ,Lin J,Yang H,et al.MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer [J]. J Biol Chem, 2008,283(45):31079-31086.
[66] Wormke M,Stoner M,Saville B,et al.The aryl hydrocarbon receptor mediates degrada- tion of estrogen receptor alpha through activation of proteasomes [J]. Mol Cell Biol, 2003,23(6):1843-1855.
[67] Nawaz Z,Lonard DM,Dennis AP,et al.Proteasome-dependent degradation of the human estrogen receptor[J].Proc Natl Acad Sci USA,1999,96(5):1858-1862.
[68] Chu I,Arnaout A,Loiseau S,et al.Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer[J].J Clin Invest,2007,117(8):2205-2215.
[69] Shao W,Keeton EK,Mcdonnell DP,et al.Coactivator AIB1 links estrogen receptor transcriptional activity and stability[J].Proc Natl Acad Sci USA,2004,101 (32):11599 -11604.
[70] Luo M,Koh M,Feng J,et al.Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation[J].Mol Cell Biol,2005,25 (16):7386-7398.
[71] Nakajima A,Maruyama S,Bohgaki M,et al.Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP [J].Biochem Biophys Res Commun,2007,357(1):245-251.
[72] Eakin CM,Maccoss MJ,Finney GL,et al.Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase [J].Proc Natl Acad Sci USA,2007,104(14):5794-5799.
[73] Duong V,Boulle N,Daujat S, et al.Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents[J].Cancer Res,2007, 67(11):5513-5521.
[74] Tateishi Y,Kawabe Y,Chiba T, et al.Ligand-dependent switching of ubiquitin- proteasome pathways for estrogen receptor[J].EMBOJ,2004,23(24): 4813- 4823.
[75] Reid G,Metivier R,Lin CY,et al. Multiple mechanisms induce transcriptional silencing of a subse tof genes, including oestrogenreceptor a, in response to deacetylase inhibit- tion by valproic acidand trichostatin A[J].Oncogene,2005,24(31):4894-4907.
[76] Grisouard J,Medunjanin S,Hermani A,et al.Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full trans- criptional activity of the receptor[J].Mol Endocrinol,2007,21(10):2427-2439.
[77] Park S,Song J,Joe CO,et al.Akt stabilizes estrogen receptor alpha with the concomi- tant reduction in its transcriptional activity[J].Cell Signal,2008,20(7):1368 -1374.
[78] Wei X,Xu H,Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha[J].Mol Cell,2006,21(2):295-305.
[79] Fan M,Bigsby RM,Nephew KP. The NEDD8 pathway is required for proteasome- mediated degradation of human estrogen receptor(ER)-alpha and essential for the antiproliferative activity of ICI182,780 in ERalpha-positive breast cancer cells[J].Mol Endocrinol,2003,17(3):356-365.
[80] Subramanian K,Jia D,Kapoor-Vazirani P,et al.Regulation of estrogen receptor alphaby the SET7 lysine methyltransferase [J]. Mol Cell,2008,30(3):336-347.
[81]Lapidus RG,Ferguson AT,Ottallano YL,et al.Methylation of estrogen and progesterone receptor gene 5’CPG islands with lack of estrogen and progesterone receptor gene expression in breast tumors[J].Clin Cancer Res,1996,2(5):805-810.
[82] Ferguson AT,Lapidus RG,Davidson NE. Demethylation of the progesterone receptor CPG island is not required to progesterone receptor gene expression [J]. Oncogene, 1998,17(5):577-583.
[83] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancer cells[J].Cancer Res,1998,58(23): 5310-5314.
[84] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[85] Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogenreceptor beta and variant isoforms in human breast cancer[ J].Cancer Res, 1999,59(21):5425-5428.
[86]罗仁峰.乳腺癌组织pS2与雌激素和孕激素受体的关系及预后意义[J].亚太传统医药,2008,4(7):11-12.
[87]刘铁成,鲁智,陶仪声,等.乳腺癌pS2、PSA与ER、PR的关系及预后意义[J].蚌埠医学院学报,2004,29(6):487-488.
[88] Maynadier M, NirdéP, Ramirez JM, et al. Role of estrogens andtheir receptors in adhesion and invasiveness of breast cancer cells[J].Adv Exp Med Biol,2008,617:485 -491.
[89] Cui XJ, Schiff R, Arpino G, et al.Biology of progesterone receptorloss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23:7721-7735.
[90] Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J].Breast,2003,12:362-367.
[91] Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive,progesterone receptor negative breast cancer:Association with growth factor receptor expression and tamo- xifen resistance[J]. J Natl Cancer Inst , 2005,97:1254-1261.
[92]王圆,叶剑飞,方文星. ER+/ PR+、ER+/ PR-乳腺癌的临床病理特征及预后分析[J].现代肿瘤医学,2009,4(4):1-4.
[93] Dowsett M. on behalf of the ATAC trialists group: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status [J]. Breast Cancer Res Treat, 2003 (suppl 1),82:S7.
[94] Bardou VJ, Arpino G, Elledge RM, et al.Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocr- ine therapy in two large breast cancer data-bases[J].J Clin Oncol,2003,21:1973 -1979.
[95] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer,the so-called triple-negative phenotype: a population-based study from the California Cancer Registry [J]. Cancer, 2007, 109(9):1721-1728.
[96] Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Can-cer Registry,1999- 2004[J].Cancer,2008, 112(4):737-747.
[97] Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J].Breast Cancer Res Treat,2008,111(1):27-44.
[98] Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stageⅡ/Ⅲbreast cancer treated with neoadjuvant doce-taxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J].BMC Cancer,2007,7:203.
[99]王蓓,傅健飞,吕晓皑.74例三阴性乳腺癌临床特征及预后分析[J].肿瘤学杂志,2009,15(11):1005-1008.
[100] Dowsett M,Allred C,Knox J,et al.Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor2(HER-2)status with recurrence in the Arimidex,Tamoxifen,Alone or in combination trial[J].J Clin Oncol,2008,26:1059-1065.
[101] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer,2007,14(2):200-214.
[102] Colleoni M,Viole G, Zahrieh D,et al. Expression of ER, PgR, HER1, HER-2, and response: a study of preoperative chemotherapy[J].Ann Oncol, 2008,19(3):465-72.
[103]李嗣杰,韩冰,付彤,等. ER、PR和HER-2的表达状况与乳腺癌新辅助化疗反应的关系[J].中国老年学杂志,2009,29(4):474-476.
[104] Tiezzi DG,Andrade JM,Tiezzi MG,et al.HER-2, P53, P21 and Hormone receptors proteins expression aspredictive factors of response and prognosis in locally advanc- ed breast cancer treated with neoadjuvant doce-taxel plus epirubicin combination[J]. BMC Cancer,2007,26(7):36.
[105] Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer[J].J Natl Cancer Inst ,2003,95:142-153.
[106]周苏娜,张明鑫,莫非,等.Iressa对ER表达状态不同的乳腺癌细胞增殖的影响[J].现代肿瘤医学,2007,17(3):397-399.
[107]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[108]刘铁成,李德春,陶仪声,等.乳腺癌中pS2与PSA相关性的研究[J].中华全科医学,2009,7(10):1024-1025.
[109]陈蕾,徐绮腻,郑瑾,等.乳腺癌临床特征与预后分析[J].中华肿瘤防治杂志,2007,14(15):1159-1162.
[110] Riva C,Dainese E,Caprara G. Study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma[J].Vimhows Arch,2005, 447(4):695-700.
[111] Toth FS,Cheek J,Calhoun K,et a1.Estrogen and androgen receptors as comediators of breast cancer cell proliferation:providing a new therapeutic tool [J].Arch Surg,2004,139(1):5O-54.
[112] Garreau JR,Muller P,Pommier R.Transgetic introduction of androgen receptor into estrogen-receptor-,progesterone-receptor-,and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation[J].Am J Surg,2006, 191(5):576-580.
[113]陈承祺,吉国力,陈舒婷,等.绝经前乳腺疾病患者性腺轴系激素水平量化分析及其临床意义[J].中华肿瘤防治杂志,2008,15(18):1404-1407.
[114] James D,Yager PHD ,Nancy E , et al . Estrogen Carcinogenesisin Breast cancer [J]. Nengl T Med ,2006 ,354:270-282.
[115]胡名柏,谢伟,熊斌,等.血浆类固醇性激素水平与女性乳腺癌危险性的关系[J].武汉大学学报(医学版),2004,25(6):694-697.
[116]马小平,徐冰,戴淑真,等.孕激素对乳腺癌细胞中雌激素代谢酶的影响[J].中国妇幼保健,2009,24(16):2263-2266.
[117]林青,李华.血清雌二醇睾酮水平与女性乳腺癌的关系[J].山东医学高等专科学校学报,2006,28(4):259-261.
[118]孙秀,李海平,李云涛,等.血清睾酮水平与绝经后乳腺癌转移复发及预后的关系[J].山东医药2009,49(36):36-38.
[119] Micheli A, Meneghini E, Secreto G, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients [J]. J Clin Oncol, 2007, 25(19):2685-2690.
[120] Berrino F, Pasanisi P, Bellati C, et al. Serum testosterone levels and breast cancer recurrence [J].Int J Cancer,2005,113(3):499-502.
[121] Pasanisi P, Berrino F, De PetrisM, et al. Metabolic syndrome as aprognostic factor for breast cancer recurrences [J].Int J Cancer, 2006,119(1):236-238.
[122] Xie B , Tsao SW,Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17 beta-oestradiol and testosterone [J].Carc- inogenesis,1999,20(8):1069-1078.
[123] Bross PF, Baird A, Cben G,et al.Fulvestrant in postmenopausal women with advanc- ed breast cancer[J].Clin Cancer Res,2003,9(12):313.
[124] Ingle JN,Suman VJ,Powland KM,et al.Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitotherapy:North Central Cancer Treatment Group Trial N0032[J]. J Clin Oncol,2006,24:1052-1056.
[125] Chia S, Gradishar W, Mauriac L, et al.Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemetane after prior nostroidal aromatase inhibitotherapy in postmenopausal women with homone receptor positive, advanced breast cancer:results from EFECT[J]. J Clin Oncol,2008,26:1664-1670.
[126] Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamo- xifen in postmenopausal women with early breast cancer[J].N Engl J Med,2005,353 (26):2747-2757.
[128] Arimidex,tamoxifen,Alone or in combination (ATAC) Trialists’group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100- month analysis of the ATAC trial.Lancet Oncol,2008,9(1):45-53.
[129] Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised tria1 by Arimidex Study Group[J].J Clin Oncol, 2000,18(22):3758-3767.
[130] Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first- line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].Clin Oncol,2003,2l(11):2101-2109.
[131] Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phaseⅢmulticenter study of exemestane versus tamoxifen as first-1ine hormone therapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,l4(9):1391 - 1398.
[132] Forward DP,Cheung KL, Jackson L, et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer[J].Br J Cancer,2004,90(3):590-594.
[133] Milla Santos A,Milla L,Calvo N,et al. Anastrozole as neoadjuvanttherapy for patients with hormone-dependent, locally-advanced breast cancer[J].Anti cancer Res, 2004,24(2):1315-1318.
[134] Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausalwomen with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG Trial 8 and ARNO 95 Trial[J].Lancet, 2005,366(9484):455-462.
[135] Coombes RC,Kilburn LS,Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years of tamoxifen treatment (Intergroup exemestane study): A randomized controlled trial [J]. Lancet,2007,369(8):559-570.
[136] Kaufmann M, Jonat W, Hilfrich J, et al.Improve overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen:The ARNO 95 study[J].J Clin Oncol,2007,25(13):2664-2670.
[137]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067-1070.
[138] Baum M,Hackshaw A,Houghton J, et al. Adjuvant goserelin in premenopausal patients with early breast cancer: results from the ZIPP study [J].Eur J Cancer, 2006,42(7):895-904.
[139] Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer[J]. Eur J Cancer,2003,39(12):1711-1717.
[140] Jakesz R,Hausmaninger H,Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,methotrexate, and fluorouraci:levidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer Austrian Breast and Colorectal Cancer Study Group Trial 5 [J]. J Clin Oncol,2002,20(24):4621-4627.
[2] James D,Yager PHD,Nancy E,et al . Estrogen Carcinogenesis in Breast cancer [J]. Nengl T Med ,2006 ,354:270-282.
[3]马小平,徐冰,戴淑真,等.孕激素对乳腺癌细胞中雌激素代谢酶的影响[J].中国妇幼保健,2009,24(16):2263-2266.
[4]胡名柏,谢伟,熊斌,等.血浆类固醇性激素水平与女性乳腺癌危险性的关系[J].武汉大学学报(医学版),2004,25(6):694-697.
[5] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2): 200-214.
[6]林青,李华.血清雌二醇睾酮水平与女性乳腺癌的关系[J].山东医学高等专科学校学报,2006,28(4):259-261.
[7]孙秀,李海平,李云涛,等.血清睾酮水平与绝经后乳腺癌转移复发及预后的关系[J].山东医药2009,49(36):36-38.
[8] Micheli A, Meneghini E, Secreto G, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients [J]. J Clin Oncol, 2007, 25(19):2685-2690.
[9] Berrino F, Pasanisi P, Bellati C, et al. Serum testosterone levels and breast cancer recurrence [J].Int J Cancer,2005,113(3):499-502.
[10] Pasanisi P, Berrino F, De PetrisM, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences [J].Int J Cancer, 2006, 119(1):236-238.
[11] Xie B , Tsao SW,Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17 beta-oestradiol and testosterone [J].Carci- nogenesis,1999,20(8):1069-1078.
[12] Robinson-Rechavi M,Escriva Garcia H,Laudet V. The nuclear receptor superfamily. J Cell Sci,2003,116(4):585-586.
[13] Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer[ J].Cancer Res, 1999,59(21):5425-5428.
[14]罗仁峰.乳腺癌组织pS2与雌激素和孕激素受体的关系及预后意义[J].亚太传统医药,2008,4(7):11-12.
[15] Maynadier M, NirdéP, Ramirez JM, et al. Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells [J]. Adv Exp Med Biol,2008,617:485- 491.
[16] Cui XJ, Schiff R, Arpino G, et al.Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23:7721-7735.
[17] Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J]. Breast,2003,12:362-367.
[18] Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive,progesterone receptor negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance[J]. J Natl Cancer Inst , 2005,97:1254-1261.
[19]王圆,叶剑飞,方文星.ER+/ PR+、ER+/ PR-乳腺癌的临床病理特征及预后分析[J].现代肿瘤医学,2009,4(4):1-4.
[20] Dowsett M. On behalf of the ATAC trialists group: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status[J]. Breast Cancer Res Treat, 2003 (suppl 1),82:S7.
[21] Bardou VJ, Arpino G, Elledge RM, et al.Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer data bases[J].J Clin Oncol,2003,21:1973- 1979.
[22] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer,the so-called triple-negative phenotype: a population-based study from the California Cancer Registry [J]. Cancer, 2007,109(9):1721-1728.
[23] Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor- negative,invasive breast cancer: the California Cancer Registry,1999-2004 [J].Cancer, 2008,112(4):737-747.
[24] Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J].Breast Cancer Res Treat,2008,111(1):27-44.
[25] Keen JC,Yan L,Mack KM,et al.A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine[J].Breast Cancer Res Treat,2003,81(3):177-186.
[26]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[27] Riva C,Dainese E,Caprara G. Study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma[J] . Vimhows Arch,2005, 447(4):695-700.
[28] Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the HER-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway[J].Mol Cell Biol,2004,24(19):8681-8690.
[29] Madureira PA,Varshochi R,Constantinidou D,et al.The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells[J].J Biol Chem,2006,281(35):25167-25176.
[30]陈蕾,徐绮腻,郑瑾,等.乳腺癌临床特征与预后分析[J].中华肿瘤防治杂志,2007,14(15):1159-1162.
[31] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[32] Fan J,Yin WJ,Lu JS,et al.ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor[J].J Cancer Res Clin Oncol,2008,134(8) :883-890.
[33] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancercells[J].Cancer Res,1998,58(23): 5310-5314.
[34]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067 -1070.
[35] Raphae ML , Vanessa D, Audrey C, et al. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells[J]. Biochemical Pharmacology, 2004, 68(4): 1239.
[36] Yu X, Guo ZS,Marcu MG, et al. Modulation of p53, ErbB1,ErbB2, and Raf-1 expression in lung cancer cells of depsipeptide FR901228 [J].J Natl Cancer Inst,2002, 94(7): 504-513.
[37] Fuino L,Bali P,Wittmann S,et al. Histone deacetylase inhibitor LAQ824 down- regulates HER-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B [J]. Mol Cancer Ther, 2003,2(10):971-984.
[38] Reid G,Metivier R,Lin CY,et al. Multiplemechanisms induce transcriptional silencing of a subsetofgenes, including oestrogenreceptor a, in response to deacetylase inhibit- tion by valproic acidand trichostatin A [J]. Oncogene,2005,24(31):4894-4907.
[39]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J].中国临床药理学与治疗学,2006,11(9):1013-1016.
[40] Gomez BP,Riggins RB,Shajahan AN,et al.Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines[J]. FASEB J,2007,21(14):4013-4027.
[41] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[1]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067 -1070.
[2] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2): 200-214.
[3]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[4] Toth FS,Cheek J,Calhoun K,et a1.Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool[J].Arch Surg,2004,139(1):5O-54.
[5] Garreau JR,Muller P,Pommier R.Transgetic introduction of androgen receptor into estrogen-receptor-,progesterone-receptor-,and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation [J].Am J Surg, 2006, 191(5):576-580.
[6]刘铁成,李德春.乳腺癌中pS2、PSA与其他预后因素的相关性[J].江苏医药,2010,36(23):2757-2759.
[7] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[8] Ottoviano YL,Issa JP,Parl FF,et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells[J].Can- cer Res,1994,54(10):2552-2555.
[9] Lapidas RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation- specific polymerase chain reaction[J]. Cancer Res,1998,58 (12):2515- 2519.
[10] Zhao L,Wang L,Jin F,et al.Silencing of estrogen receptor alpha(ERalpha)gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer[J].Breast Cancer Res Treat,2009,117(2) :253-259.
[11] Yan L,Nass SJ,Smith D,et al.Specific inhibition of DNMT1 by antisense oligonucleo- tides induces re-expression of estrogen receptor-alpha(ER) in ER-negative human breast cancer cell lines[J].Cancer Biol Ther,2003,2(5) :552-556.
[12] Fu XH, Liu DP, Liang CC. Chromatin structure and transcription regulation of theβ-globin locus[J]. Exp Cell Res,2002,278(1):1.
[13] Berger SL. Histone modifications in transcriptional regulation[J]. Curr Opin Genet, 2002,12:142.
[14] Jenuwein T, Allis CD. Translating the histone code[J]. Science,2001,293(5532): 1074.
[15] Stiehl DP, Fath DM, Liang D, et al. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. Cancer Res. 2007,67:2256–2264.
[16] Hochedlinger K, Blelloch R, Brennan C,et al. Reprogramming of amelalloma genome by nuclear transplantation [J]. Genes Dev,2004,1(8): 1875-1885.
[17] Suzuki J,Chen YY,Scott GK,et al.Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression[J].Clin Cancer Res, 2009,15(9):3163-3171.
[18] Kawai H,Li H,Avraham S,et al.Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha[J].Int J Cancer,2003,107(3):353-358.
[19] Yang X,Ferguson AT,Nass SJ,et al.Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition[J].Cancer Res, 2000,60(24):6890-6894.
[20] Fuks F,Hurd PJ,Wolf D,et al.The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation[J].J Biol Chem,2003,278(6):4035-4040.
[21] Sharma D,Blum J,Yang X,et al.Release of methyl CpG binding proteinsand histone deacetylase 1 from the Estrogen receptor alpha (ER)promoter upon reactivation in ER-negative human breast cancer cells[J].Mol Endocrinol,2005,19(7):1740-1751.
[22] Keen JC,Yan L,Mack KM,et al.A novel histone deacetylase inhibitor,scriptaid,enhances expression of functional estrogen receptor alpha(ER) in ER negative human breast cancer cells in combination with 5-aza2’-deoxycytidine[J].Breast Cancer Res Treat,2003,81(3):177-186.
[23] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancer cells[J].Cancer Res,1998,58(23): 5310-5314.
[24] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[25] Ferguson AT,Lapidus RG,Davidson NE.Demethylation of the progesterone receptor CPG island is not required to progesterone receptor gene expression[J]. Oncogene, 1998,17(5):577-583.
[26] Lapidus RG,Ferguson AT,Ottallano YL,et al.Methylation of estrogen and progestero- ne receptor gene 5’CPG islands with lack of estrogen and progesterone receptor gene expression in breast tumors[J].Clin Cancer Res,1996,2(5):805-810.
[27]刘铁成,李德春,陶仪声,等.乳腺癌中pS2与PSA相关性的研究[J].中华全科医学,2009,7(10):1024-1025.
[28] Fan J,Yin WJ,Lu JS,et al.ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor[J].J Cancer Res Clin Oncol,2008,134(8):883-890.
[29] Ishiguro K,Sartorelli AC.Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/ a poptosis-dimethylsulfoxide,hexamethylene bisacetamide and trichostatin A[J].Eur J Biochem,2004,271(12): 2379-2390.
[30]范江,陆劲松,沈镇宙,等.5-aza-2’-deoxycytidine联合trichostatin A抑制乳腺癌细胞增殖能力的研究[J].中国癌症杂志,2006,16(5):329-332.
[31] Hortobagyi GN. Treatment of breast cancer[J].N Engl J Med, 1998, 339: 974–984.
[32]江明,邵志敏,张亚伟等.ER阳性和ER阴性人乳腺癌细胞株p53、mdm-2、及p21WAFI蛋白表达的研究[J].中华病理学杂志,1997,12(6):327-330.
[33] Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment[J].Gynecol Oncol,2004,94(2):256-266.
[34] Gayther SA,Batley SJ,Linger,et al. Mutations truncating the P300 acetylase in human cancers[J].Nat Genet,2000,24(3):300.
[35] Zheng L,Annab LA,Afshari CA,et al. BRCA1 mediates ligand-independent transcri- ptional repression of the estrogen receptor[J]. Proc Natl Acad Sci USA,2001,98(17): 9587.
[36] Margueron R,Duong V,Bonnet S,et al. Histone deacetylase activity and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens[J].J Mol Endocrinol,2004,32(2):1957.
[37] Christian M,Tullet JM,Parker MG. Characterisation of four autonomous repression domains in the corepressor RIP140[J]. J Biol Chem, 2004, 279(8):15645.
[38] Castet A,Boulahtouf A,Versini G,et al. Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibittion[J]. Nucl Acids Res,2004,32(5): 1957.
[39] Kurtev V,Margueron R,Kroboth K,et al. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases [J]. J Biol Chem , 2004,279(21):24834.
[40] Raphae Ml , Vanessa D, Audrey C, et al. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells[J]. Biochemical Pharmacology, 2004, 68(4): 1239.
[41] Cameron EE,Bachman KE,Myohamens.Synergy of demethylation and histone deace- tylase inhibition in the re-expression of genes silenced in cancer[J].Nat Genet,1999, 21(1):103-107.
[42] Yuan Y, Qin L, Liu D, et al. Genetic screening reveals an essential role of p27Kip1in restriction of breast cancer progression[J]. Cancer Res,2007,67(17):8032-8042.
[43]谢瑞莲,管晓翔,陈龙邦,等.丁酸钠对人乳腺癌细胞株MCF-7细胞增殖及p27Kip1蛋白表达影响的研究[J].中华肿瘤防治杂志,2008,15(14):1041-1044.
[44]邓放,王广义,任强.MS-275与表阿霉素合用对乳腺癌MCF-7细胞的影响[J].中国妇幼保健,2007,22(31):4466-4468.
[45] Holger HS, Tomke UB, David H,et al. MS-275, a potent orally vailable inhibitor of histone deacetylases-The development of an anticancer agent[J]. Int J Bio & Cell Bio, 2007,16:23
[46] Reid G,Metivier R,Lin CY,et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor a, in response to deacetylase inhi- bittion by valproic acidand trichostatin A [J]. Oncogene,2005,24(31):4894-4907.
[47] Fuino L,Bali P,Wittmann S,et al. Histone deacetylase inhibitor LAQ824 down - regulates HER-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B [J]. Mol Cancer Ther, 2003,2(10):971-984.
[48]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J ].中国临床药理学与治疗学,2006,11(9):1013- 1016.
[49] Byrd JC, Marcucci G, Parthun MR,et al. Aphase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acutemyeloid leukemia [J].Blood,2005,105(3):959-967.
[50]易欣,赵名,张旭辉,等.组蛋白去乙酰化酶抑制剂FK228通过阻断HSP90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5):349-353.
[51] Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J].J Cell Mol Med,2005,9(2):360-372.
[52] Reid T, Valone F, Lipera W,et al. PhaseⅡtrial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer [J]. Lung Cancer,2004, 45(3):381-386.
[53] Yu X, Guo ZS,Marcu MG, et al. Modulation of p53, ErbB1,ErbB2, and Raf-1 expre- ssion in lung cancer cells of depsipeptide FR901228 [J]. J Natl Cancer Inst,2002,94 (7): 504-513.
[54] Lee MO,Kim EO,Kwon HJ,et al. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shockprotein 90[J]. Mol Cell Endocrinol, 2002, 188(1-2): 47-54.
[55] Franco S,Perez A,Tan-Chiu E,et al. Response to fulvestrant in heavily pretreated postmenopausalwomen:a single center experience[J]. Breast Cancer Res Treat,2004, 88(2): 103-108.
[56] Moradei O, Maroun CR, Paquin I,et al. Histone deacetylase inhibitors: latest developments, trends and prospects[J]. Curr Med Chem Anticancer Agents,2005,5 (5):529-560.
[57] Schiff R,Massarweh S,Shou J,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen geldanamycin and tamoxifen-resistant breast cancer receptor coregulators modulate response [J]. Clin Cancer Res,2003,9(1Pt2):447-454.
[58] Colleoni M,Viole G, Zahrieh D,et al.Expression of ER, PgR,HER1,HER-2, and response: a study of preoperative chemotherapy[J].Ann Oncol, 2008,19(3):465-72.
[59] Dowsett M,Allred C,Knox J,et al.Relationship between quantitativeestrogen and pro- gesterone receptor expression and human epidermal growthfactor receptor2 (HER-2) status with recurrence in the Arimidex,Tamoxifen,Alone or in combination trial[J].J Clin Oncol,2008,26:1059-1065.
[60]唐鹏编译.美国ASCO年会拾贝:一种新型的组蛋白脱乙酰基酶抑制剂OSU-HDAC42对HER-2阳性乳腺癌有抗肿瘤作用[J/CD].中华乳腺病杂志(电子版),2009,3(5):568.
[61]王丹,陈宇鹏,梁静等.HDAC抑制剂TSA抑制乳腺癌MCF-7细胞增殖并促进乳腺癌细胞凋亡[J].中国生物化学与分子生物学报,2009,25(6):570-573.
[1] Peedicayil J.The role of epigenetics inmental disorders[J]. Indian J Med Res,2007,126 (2):105-111.
[2] Arts J,de Schepper S,Van Emelen K.Histone deacetylase inhibitors:from chromatin remodeling to experimentalcancer therapeutics[J].Curr Med Chem,2003,10(22): 2343-2350.
[3] Jair KW,Bachman KE,Suzuki H,et al.Denovo CpG island methylation in human cancer cells[J]. Cancer Res,2006,66(2):682-692.
[4]周小娟,王云梅,刘娟,等.5-氮杂-2′-脱氧胞苷逆转RASSF1A基因甲基化对人乳腺癌MCF-7细胞的影响[J].第四军医大学学报,2009,30(21):2327-2331.
[5] Robertson KD.DNA Methylation and Human Disease[J].Nat Rev Genet,2005,6 (8): 597-610.
[6] Okuda Y, Kawakami K, Ishiguro K,et al. The profile of hMLH1 methylation and microsatellite instability in colorectal and non-small cell lung cancer[J].Int Mol Med,2005,15(1):85-90.
[7] Erdamar S,Ucaryilmaz E, Dogusoy G. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer[J].World J Gastroenterol,2007,13(33):4437-4444.
[8] Jeon CH,Lee HI,Shin IH.Genetic alterations of APC,K-ras,p53,MSI, and MAGE in Korean colorectal cancer patients [J]. Int J Colorectal Dis, 2008, 23(1): 29-35.
[9] Schmutte C ,Yang AS,Beart RW,et al. Base excission repair of U:GMismatches at a mutational hotspot in the P53 gene is more efficient than base excision repaire of T:G mismatches in extracts of human colon tu-mors [J]. Cancer Res, 1995, 55 (17) : 3742- 3746.
[10] Mamatha G,Joseph B,Shanmugam MP,et al. CGA codonsmultiplex PCR in rapid diagnosis of retinoblastoma[J].Indian J Hum Genet,2006,12(1): 34-38.
[11] Luczak MW, Jagodzinski PP.The role of DNA methylation in cancer development[J]. Folia Histochem Cytobiol,2006,44(3):143-154.
[12] Polanowska J,Martin JS,Garcia-Muse T,et al. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage site[J].EMBO J, 2006,25(10):2178 -2188.
[13] Agrawal S,Unterberg M,Koschmieder S.DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia[J].Cancer Res,2007,67(3):1370-1377.
[14] Issa JP.DNA Methylation as a therapeutic target in cancer[J].Clin Cancer Res,2007,13 (6):1634-1637.
[15] Chen RZ,Pettersoon U,Beard C,et al. DNA hypomethylation leads to elevated mutation rates[J].Nature,1998,395(6697):89-93.
[16] Lengauer C,Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells[J]. Proc Natl Acad Sci USA,1997,9(4): 2545-2550.
[17] Brueckner B,Stresemann C,Kuner R,et al.The human let-7a-3 locus contains an epigentically regulated microRNA gene with oncogenic function[J].Cancer Res,2007, 67(14):19-23.
[18] Luo D, Zhang B,Lv L,et al. Methylation of CpG island of p16 associated with progression of primary gastric carcinomas[J].Lab Invest, 2006, 86(6): 591-598.
[19] Beier V,Mund C,Hoheisel JD. Monitoring methylation changes in cancer[J]. Adv Biochem Eng Biotechnol,2007,10(4):1-11.
[20] Esteller T. Detection and interpretation of altered methylation patterns in cancer cells[J].N Engl J Med,2008,358(11):48-59.
[21] Hochedlinger K, Blelloch R, Brennan C,et al. Reprogramming of amelalloma genome by nuclear transplantation [J]. Genes Dev,2004,1(8): 1875-1885.
[22] Gayther SA,Batley SJ,Linger,et al. Mutations truncating the P300 acetylase in human cancers [J].Nat Genet,2000,24(3):300.
[23] Zheng L,Annab LA,Afshari CA,et al. BRCA1 mediates ligand-independent transcrip-tional repression of the estrogen receptor [J]. Proc Natl Acad Sci USA,2001,98(17): 9587.
[24] Wang L,Devarajan E,He J,et al. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression[J].Cancer Res,2005,65(22):10289-10297.
[25]王磊,胡英,杨祖立,等.乳腺癌细胞中Syk( L)调节基因转录的生物学机制[J].癌症,2007,26(5):469-472.
[26] Margueron R,Duong V,Bonnet S,et al. Histone deacetylase activity and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens[J].J Mol Endocrinol,2004,32(2):1957.
[27] Christian M,Tullet JM,Parker MG. Characterisation of four autonomous repression domains in the corepressor RIP140[J]. J Biol Chem, 2004, 279(8):15645.
[28] Castet A,Boulahtouf A,Versini G,et al. Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibittion [J]. Nucl Acids Res,2004,32 (5): 1957.
[29] Kurtev V,Margueron R,Kroboth K,et al. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases [J]. J Biol Chem , 2004,279(21):24834.
[30]蔡飏,孙晋枫,黄朝晖,等.ABCC8、CHFR、BMP3B、LOX、PRSS21和RASSF1A基因启动子的甲基化状态可能与3种乳腺癌细胞株对5-FU的敏感性相关[J].肿瘤,2009,29(1):20-25.
[31]范江,陆劲松,沈镇宙,等.5-aza-2’-deoxycytidine联合trichostatin A抑制乳腺癌细胞增殖能力的研究[J].中国癌症杂志,2006,16(5):329-332.
[32] Chuang JC,Yoo CB,Kwan JM,et al.Comparison of biological effects of non-nucleo- side DNA methylation inhibitors versus 5-aza-2-deoxycytidine [J].Mol Cancer Ther, 2005,4(10):1515-1521.
[33] Segura Pacheco B,Trejo Becerril C,Perez Cardenas E,et al.Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy[J]. Clin Cancer Res,2003,9(5):1596-1603.
[34]任香,罗达亚,刘丽乔,等.肼苯哒嗪对人乳腺癌细胞株MDA-MB-231雌激素受体α去甲基化的影响[J].江西医学院学报,2009,49(3):26-29.
[35]陈伟,王留兴,樊青霞,等.三氧化二砷和肼苯哒嗪体外诱导雌激素受体表达强弱的比较[J].肿瘤基础与临床,2007,20(3):208-209.
[36]王丹,陈宇鹏,梁静等.HDAC抑制剂TSA抑制乳腺癌MCF-7细胞增殖并促进乳腺癌细胞凋亡[J].中国生物化学与分子生物学报,2009,25(6):570-573.
[37] Yuan Y, Qin L, Liu D, et al. Genetic screening reveals an essential role of p27Kip1in restriction of breast cancer progression[J]. Cancer Res,2007,67(17):8032-8042.
[38]谢瑞莲,管晓翔,陈龙邦,等.丁酸钠对人乳腺癌细胞株MCF-7细胞增殖及p27Kip1蛋白表达影响的研究[J].中华肿瘤防治杂志,2008,15(14):1041-1044.
[39]邓放,王广义,任强.MS-275与表阿霉素合用对乳腺癌MCF-7细胞的影响[J].中国妇幼保健,2007,22(31):4466-4468.
[40] Holger HS, Tomke UB, David H,et al. MS-275,a potent orally vailable inhibitor of histone deacetylases-The development of an anticancer agent[J]. Int J Bio & Cell Bio,2007,16:23
[41]孙圣坤,刘兵,李秀森.曲古抑菌素A对前列腺癌LNCaP细胞抑制效应的细胞信号通路研究[J ].中国临床药理学与治疗学,2006,11(9):1013- 16.
[42] Byrd JC, Marcucci G, Parthun MR,et al. Aphase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acutemyeloid leukemia [J].Blood,2005,105(3):959-967.
[43]易欣,赵名,张旭辉,等.组蛋白去乙酰化酶抑制剂FK228通过阻断HSP90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5):349-353.
[44] Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J]. J Cell Mol Med,2005,9(2):360-372.
[45] Fuks F,Hurd PJ,Wolf D,et al.The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation[J].J Biol Chem,2003,278(6):4035-4040.
[46] Cameron EE,Bachman KE,Myohamens.Synergy of demethylation and histone deace- tylase inhibition in the re-expression of genes silenced in cancer[J].Nat Genet,1999,21(1):103-107.
[47] Lapidas RG,Nass SJ,Butash KA,et al.Mapping of ER gene CpG island methylation- specific polymerase chain reaction[J]. Cancer Res,1998,58(12): 2515- 2519.
[48] Zhao L,Wang L,Jin F,et al.Silencing of estrogen receptor alpha(ERalpha)gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer[J].Breast Cancer Res Treat,2009,117(2):253-259.
[49] Yan L,Nass SJ,Smith D,et al.Specific inhibition of DNMT1 by antisense oligonucleo- tides induces re-expression of estrogen receptor-alpha(ER) in ER-negative human breast cancer cell lines[J].Cancer Biol Ther,2003,2(5):552-556.
[50] Suzuki J,Chen YY,Scott GK,et al.Protein acetylation and histone deacetylase expre- ssion associated with malignant breast cancer progression[J].Clin Cancer Res,2009, 15(9):3163-3171.
[51] Kawai H,Li H,Avraham S,et al.Over-expression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha [J].Int J Cancer,2003,107(3):353-358.
[52] Yang X,Ferguson AT,Nass SJ,et al.Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition[J]. Cancer Res, 2000,60(24):6890-6894.
[53] Sharma D,Blum J,Yang X,et al.Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER)promoter upon reactivation in ER-negative human breast cancer cells[J].Mol Endocrinol,2005,19(7):1740-1751.
[54] Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha -negtive breast cancer cells[J]. Cancer Res,2001,61(19):7025-7029.
[59] Woodfield GW,Horan AD,Chen Y,et al.TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling[J].Cancer Res,2007,67 (18):8439-8443.
[60] Woodfield GW,Hitchler MJ,Chen Y,et al.Interaction of TFAP2C with the estrogenreceptor-alpha promoter is controlled by chromatin structure[J].Clin Cancer Res, 2009,15(11):3672-3679.
[61] Angeloni SV,Martin MB,Garcia-Morales P,et al. Regulation of estrogen receptor- alpha expression by the tumor suppressor gene p53 in MCF-7cells [J]. J Endocrinol, 2004,180(3):497-504.
[62] Gomez BP,Riggins RB,Shajahan AN,et al.Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines[J]. FASEB J,2007,21(14):4013-4027.
[63] Adams BD,Furneaux H,White BA.The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha(ER-a)and represses ER-alpha messenger RNA and protein expression in breast cancer cell lines[J].Mol Endocrinol,2007,21,(5) :1132-1147.
[64] Kondo N,Toyama T,Sugiura H,et al. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer[J].Cancer Res,2008,68 (13): 5004-5008.
[65] Zhao JJ,Lin J,Yang H,et al.MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer [J]. J Biol Chem, 2008,283(45):31079-31086.
[66] Wormke M,Stoner M,Saville B,et al.The aryl hydrocarbon receptor mediates degrada- tion of estrogen receptor alpha through activation of proteasomes [J]. Mol Cell Biol, 2003,23(6):1843-1855.
[67] Nawaz Z,Lonard DM,Dennis AP,et al.Proteasome-dependent degradation of the human estrogen receptor[J].Proc Natl Acad Sci USA,1999,96(5):1858-1862.
[68] Chu I,Arnaout A,Loiseau S,et al.Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer[J].J Clin Invest,2007,117(8):2205-2215.
[69] Shao W,Keeton EK,Mcdonnell DP,et al.Coactivator AIB1 links estrogen receptor transcriptional activity and stability[J].Proc Natl Acad Sci USA,2004,101 (32):11599 -11604.
[70] Luo M,Koh M,Feng J,et al.Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation[J].Mol Cell Biol,2005,25 (16):7386-7398.
[71] Nakajima A,Maruyama S,Bohgaki M,et al.Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP [J].Biochem Biophys Res Commun,2007,357(1):245-251.
[72] Eakin CM,Maccoss MJ,Finney GL,et al.Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase [J].Proc Natl Acad Sci USA,2007,104(14):5794-5799.
[73] Duong V,Boulle N,Daujat S, et al.Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents[J].Cancer Res,2007, 67(11):5513-5521.
[74] Tateishi Y,Kawabe Y,Chiba T, et al.Ligand-dependent switching of ubiquitin- proteasome pathways for estrogen receptor[J].EMBOJ,2004,23(24): 4813- 4823.
[75] Reid G,Metivier R,Lin CY,et al. Multiple mechanisms induce transcriptional silencing of a subse tof genes, including oestrogenreceptor a, in response to deacetylase inhibit- tion by valproic acidand trichostatin A[J].Oncogene,2005,24(31):4894-4907.
[76] Grisouard J,Medunjanin S,Hermani A,et al.Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full trans- criptional activity of the receptor[J].Mol Endocrinol,2007,21(10):2427-2439.
[77] Park S,Song J,Joe CO,et al.Akt stabilizes estrogen receptor alpha with the concomi- tant reduction in its transcriptional activity[J].Cell Signal,2008,20(7):1368 -1374.
[78] Wei X,Xu H,Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha[J].Mol Cell,2006,21(2):295-305.
[79] Fan M,Bigsby RM,Nephew KP. The NEDD8 pathway is required for proteasome- mediated degradation of human estrogen receptor(ER)-alpha and essential for the antiproliferative activity of ICI182,780 in ERalpha-positive breast cancer cells[J].Mol Endocrinol,2003,17(3):356-365.
[80] Subramanian K,Jia D,Kapoor-Vazirani P,et al.Regulation of estrogen receptor alphaby the SET7 lysine methyltransferase [J]. Mol Cell,2008,30(3):336-347.
[81]Lapidus RG,Ferguson AT,Ottallano YL,et al.Methylation of estrogen and progesterone receptor gene 5’CPG islands with lack of estrogen and progesterone receptor gene expression in breast tumors[J].Clin Cancer Res,1996,2(5):805-810.
[82] Ferguson AT,Lapidus RG,Davidson NE. Demethylation of the progesterone receptor CPG island is not required to progesterone receptor gene expression [J]. Oncogene, 1998,17(5):577-583.
[83] Jarrard DF,Kinoshita H,Shi Y,et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate Cancer cells[J].Cancer Res,1998,58(23): 5310-5314.
[84] Kato S,Sato T,Watanal T,et al.Function of nuclear sex homone receptors in gene regulation[J].Cancer Chemother Pharmacol,2005,56(Supp 11):4-9.
[85] Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogenreceptor beta and variant isoforms in human breast cancer[ J].Cancer Res, 1999,59(21):5425-5428.
[86]罗仁峰.乳腺癌组织pS2与雌激素和孕激素受体的关系及预后意义[J].亚太传统医药,2008,4(7):11-12.
[87]刘铁成,鲁智,陶仪声,等.乳腺癌pS2、PSA与ER、PR的关系及预后意义[J].蚌埠医学院学报,2004,29(6):487-488.
[88] Maynadier M, NirdéP, Ramirez JM, et al. Role of estrogens andtheir receptors in adhesion and invasiveness of breast cancer cells[J].Adv Exp Med Biol,2008,617:485 -491.
[89] Cui XJ, Schiff R, Arpino G, et al.Biology of progesterone receptorloss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23:7721-7735.
[90] Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer[J].Breast,2003,12:362-367.
[91] Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive,progesterone receptor negative breast cancer:Association with growth factor receptor expression and tamo- xifen resistance[J]. J Natl Cancer Inst , 2005,97:1254-1261.
[92]王圆,叶剑飞,方文星. ER+/ PR+、ER+/ PR-乳腺癌的临床病理特征及预后分析[J].现代肿瘤医学,2009,4(4):1-4.
[93] Dowsett M. on behalf of the ATAC trialists group: Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status [J]. Breast Cancer Res Treat, 2003 (suppl 1),82:S7.
[94] Bardou VJ, Arpino G, Elledge RM, et al.Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocr- ine therapy in two large breast cancer data-bases[J].J Clin Oncol,2003,21:1973 -1979.
[95] Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer,the so-called triple-negative phenotype: a population-based study from the California Cancer Registry [J]. Cancer, 2007, 109(9):1721-1728.
[96] Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Can-cer Registry,1999- 2004[J].Cancer,2008, 112(4):737-747.
[97] Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J].Breast Cancer Res Treat,2008,111(1):27-44.
[98] Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stageⅡ/Ⅲbreast cancer treated with neoadjuvant doce-taxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J].BMC Cancer,2007,7:203.
[99]王蓓,傅健飞,吕晓皑.74例三阴性乳腺癌临床特征及预后分析[J].肿瘤学杂志,2009,15(11):1005-1008.
[100] Dowsett M,Allred C,Knox J,et al.Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor2(HER-2)status with recurrence in the Arimidex,Tamoxifen,Alone or in combination trial[J].J Clin Oncol,2008,26:1059-1065.
[101] Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer,2007,14(2):200-214.
[102] Colleoni M,Viole G, Zahrieh D,et al. Expression of ER, PgR, HER1, HER-2, and response: a study of preoperative chemotherapy[J].Ann Oncol, 2008,19(3):465-72.
[103]李嗣杰,韩冰,付彤,等. ER、PR和HER-2的表达状况与乳腺癌新辅助化疗反应的关系[J].中国老年学杂志,2009,29(4):474-476.
[104] Tiezzi DG,Andrade JM,Tiezzi MG,et al.HER-2, P53, P21 and Hormone receptors proteins expression aspredictive factors of response and prognosis in locally advanc- ed breast cancer treated with neoadjuvant doce-taxel plus epirubicin combination[J]. BMC Cancer,2007,26(7):36.
[105] Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer[J].J Natl Cancer Inst ,2003,95:142-153.
[106]周苏娜,张明鑫,莫非,等.Iressa对ER表达状态不同的乳腺癌细胞增殖的影响[J].现代肿瘤医学,2007,17(3):397-399.
[107]吴晓莉,吴名耀,吴贤英,等.雄激素受体在乳腺癌组织中的表达及临床意义[J].汕头大学医学院学报,2008,21(2):81-83.
[108]刘铁成,李德春,陶仪声,等.乳腺癌中pS2与PSA相关性的研究[J].中华全科医学,2009,7(10):1024-1025.
[109]陈蕾,徐绮腻,郑瑾,等.乳腺癌临床特征与预后分析[J].中华肿瘤防治杂志,2007,14(15):1159-1162.
[110] Riva C,Dainese E,Caprara G. Study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma[J].Vimhows Arch,2005, 447(4):695-700.
[111] Toth FS,Cheek J,Calhoun K,et a1.Estrogen and androgen receptors as comediators of breast cancer cell proliferation:providing a new therapeutic tool [J].Arch Surg,2004,139(1):5O-54.
[112] Garreau JR,Muller P,Pommier R.Transgetic introduction of androgen receptor into estrogen-receptor-,progesterone-receptor-,and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation[J].Am J Surg,2006, 191(5):576-580.
[113]陈承祺,吉国力,陈舒婷,等.绝经前乳腺疾病患者性腺轴系激素水平量化分析及其临床意义[J].中华肿瘤防治杂志,2008,15(18):1404-1407.
[114] James D,Yager PHD ,Nancy E , et al . Estrogen Carcinogenesisin Breast cancer [J]. Nengl T Med ,2006 ,354:270-282.
[115]胡名柏,谢伟,熊斌,等.血浆类固醇性激素水平与女性乳腺癌危险性的关系[J].武汉大学学报(医学版),2004,25(6):694-697.
[116]马小平,徐冰,戴淑真,等.孕激素对乳腺癌细胞中雌激素代谢酶的影响[J].中国妇幼保健,2009,24(16):2263-2266.
[117]林青,李华.血清雌二醇睾酮水平与女性乳腺癌的关系[J].山东医学高等专科学校学报,2006,28(4):259-261.
[118]孙秀,李海平,李云涛,等.血清睾酮水平与绝经后乳腺癌转移复发及预后的关系[J].山东医药2009,49(36):36-38.
[119] Micheli A, Meneghini E, Secreto G, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients [J]. J Clin Oncol, 2007, 25(19):2685-2690.
[120] Berrino F, Pasanisi P, Bellati C, et al. Serum testosterone levels and breast cancer recurrence [J].Int J Cancer,2005,113(3):499-502.
[121] Pasanisi P, Berrino F, De PetrisM, et al. Metabolic syndrome as aprognostic factor for breast cancer recurrences [J].Int J Cancer, 2006,119(1):236-238.
[122] Xie B , Tsao SW,Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17 beta-oestradiol and testosterone [J].Carc- inogenesis,1999,20(8):1069-1078.
[123] Bross PF, Baird A, Cben G,et al.Fulvestrant in postmenopausal women with advanc- ed breast cancer[J].Clin Cancer Res,2003,9(12):313.
[124] Ingle JN,Suman VJ,Powland KM,et al.Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitotherapy:North Central Cancer Treatment Group Trial N0032[J]. J Clin Oncol,2006,24:1052-1056.
[125] Chia S, Gradishar W, Mauriac L, et al.Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemetane after prior nostroidal aromatase inhibitotherapy in postmenopausal women with homone receptor positive, advanced breast cancer:results from EFECT[J]. J Clin Oncol,2008,26:1664-1670.
[126] Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamo- xifen in postmenopausal women with early breast cancer[J].N Engl J Med,2005,353 (26):2747-2757.
[128] Arimidex,tamoxifen,Alone or in combination (ATAC) Trialists’group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100- month analysis of the ATAC trial.Lancet Oncol,2008,9(1):45-53.
[129] Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised tria1 by Arimidex Study Group[J].J Clin Oncol, 2000,18(22):3758-3767.
[130] Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first- line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].Clin Oncol,2003,2l(11):2101-2109.
[131] Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phaseⅢmulticenter study of exemestane versus tamoxifen as first-1ine hormone therapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,l4(9):1391 - 1398.
[132] Forward DP,Cheung KL, Jackson L, et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer[J].Br J Cancer,2004,90(3):590-594.
[133] Milla Santos A,Milla L,Calvo N,et al. Anastrozole as neoadjuvanttherapy for patients with hormone-dependent, locally-advanced breast cancer[J].Anti cancer Res, 2004,24(2):1315-1318.
[134] Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausalwomen with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG Trial 8 and ARNO 95 Trial[J].Lancet, 2005,366(9484):455-462.
[135] Coombes RC,Kilburn LS,Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years of tamoxifen treatment (Intergroup exemestane study): A randomized controlled trial [J]. Lancet,2007,369(8):559-570.
[136] Kaufmann M, Jonat W, Hilfrich J, et al.Improve overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen:The ARNO 95 study[J].J Clin Oncol,2007,25(13):2664-2670.
[137]史玉霞,韩克,王雪晨.甲地孕酮与三苯氧胺联合应用对乳腺癌MCF-7细胞生长和凋亡的影响[J].南京医科大学学报(自然科学版),2009 ,29(8):1067-1070.
[138] Baum M,Hackshaw A,Houghton J, et al. Adjuvant goserelin in premenopausal patients with early breast cancer: results from the ZIPP study [J].Eur J Cancer, 2006,42(7):895-904.
[139] Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer[J]. Eur J Cancer,2003,39(12):1711-1717.
[140] Jakesz R,Hausmaninger H,Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,methotrexate, and fluorouraci:levidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer Austrian Breast and Colorectal Cancer Study Group Trial 5 [J]. J Clin Oncol,2002,20(24):4621-4627.